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ST2/MYD88 SIGNALING IS A THERAPEUTIC TARGET ALLEVIATING MURINE 
ACUTE GRAFT-VERSUS-HOST DISEASE SPARING T REGULATORY CELL 
FUNCTION 
 
Acute graft-versus-host disease (aGVHD) hinders the efficacy of allogeneic 
hematopoietic cell transplantation (HCT). Plasma levels of soluble serum 
stimulation-2 (sST2) are elevated during human and murine aGVHD and are 
correlated to a type 1 T cell response. Membrane-bound ST2 (ST2) on donor T 
cells has been shown to be protective against aGVHD. ST2 signals through the 
adapter protein myeloid differentiation primary response 88 (MyD88). The role of 
MyD88 signaling in donor T cells during aGVHD remains unknown. We found 
that knocking out MyD88 in the donor T cells protected against aGVHD 
independent of interleukin 1 receptor (IL-1R) and toll-like receptor 4 (TLR4) 
signaling, both of which also signal through MyD88, in two murine HCT models. 
This protection was entirely driven by MyD88-/- CD4 T cells, leading to a 
decreased type 1 response without affecting T cell proliferation, apoptosis, or 
migration. In our aGVHD models, loss of intrinsic MyD88 signaling is not 
responsible for the observed protection. However, transplanting donor MyD88-/- T 
conventional cells (Tcons) with wild type (WT) or MyD88-/- T regulatory cells 
(Tregs) ameliorated aGVHD severity and lowered aGVHD mortality. 
Transcriptome analysis of sorted MyD88-/- CD4 T cells from the intestine ten days 
vi 
post-HCT showed lower levels of Il1rl1 (gene of ST2), Ifng, Csf2, Stat5, and 
Jak2, among others. Decreased sST2 was confirmed at the protein level with 
less secretion of sST2 and more expression of ST2 compared to WT T cells. 
Transplanting donor ST2-/- Tcons with WT or ST2-/- Tregs mirrored observations 
when using donor MyD88-/- Tcons. This suggests that Treg suppression from lack 
of MyD88 signaling in Tcons during alloreactivity uses the ST2 but not the IL-1R 
or TLR4 pathways. The results of our study confirm that ST2 represents an 
aGVHD therapeutic target that spares Treg function. 
 
 
Sophie Paczesny, M.D., Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
 
1.1: Immune Response 
The immune system is composed of various effector cells and molecules that 
respond to and protect the body from bacterial, fungal, and viral infections as well 
as toxins, proteins, and other macromolecules that are recognized as foreign and 
could cause damage to the body. An effective immune response is composed of 
four components: 1) immunological recognition, 2) effector function, 3) immune 
regulation, and 4) immunological memory.1 Immunological recognition requires 
that the immune system detect the invading microbe or foreign macromolecule. 
Once recognized, the immune system begins to upregulate effector molecules to 
contain and destroy the foreign entity. While the response is ongoing, the 
immune system must be able to self-regulate both during and after the infection. 
Failure at self-regulation leads to autoimmune disease. Once an infection or 
foreign entity is cleared, the immune system can develop memory cells, which 
respond quickly to any recurring foreign antigen and clear it.  
 
1.1.1: Innate Immune System 
In humans the immune system is composed of two cooperative arms: the innate 
immune system and the adaptive immune system. The innate immune system 
rapidly responds to control and remove any infection. Activation and response of 
the innate immune system to infection relies on pattern recognition receptors 
(PRRs) either on the cell surface, in the cytoplasm, or secreted by innate immune 
2 
cells.2  These PRRs recognize pathogen-associated molecular patterns (PAMPs) 
and damage-associated molecular patterns (DAMPs), leading to effector 
response. The innate immune system is also responsible for the activation and 
modulation of the adaptive immune response through antigen presentation on 
major histocompatibility complexes (MHC) and secretion of various cytokines.3  
 
Innate immunity provides an early line of defense for the body and is composed 
of multiple components. An infection or foreign antigen must first pass the 
physical barriers of the body. These include the skin, gastrointestinal tract, 
respiratory tract, and urogenital tract. The skin, in addition to being a physical 
barrier, produces antimicrobial peptides, which can kill microbes through 
disruption of the cytoplasmic membrane, DNA and protein synthesis, and protein 
folding.4 The epithelia in the gastrointestinal, respiratory, and urogenital tracts are 
coated in mucus to prevent adherence of microbes. Cilia on these cells expel 
mucus and the microbes trapped in the mucus. Microbes which pass through the 
mucus then have to get through the epithelial barrier, which is held together with 
tight junctions. These tight junctions prevent easy passage of microbes between 
epithelial cells. Breaking of these barriers leads to microbes entering the body. 
When this happens innate immune cells are recruited to destroy the invading 
microbes. This cell-mediated immunity is facilitated by neutrophils, eosinophils, 
basophils, mast cells, monocytes, macrophages, dendritic cells (DCs), and 
natural killer cells (NK cells).5  
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Each innate immune cell type has a specific function in promoting an effective 
immune response. Neutrophils are the most abundant immune cells and are one 
of the first to migrate toward a site of infection. These cells follow chemical 
signals such as interleukin (IL)-8, N-formylmethionyl-leucyl-phenylalanine, 
Leukotriene B4, and H2O2. Once recruited, neutrophils can phagocytose 
microbes or macromolecules that have been opsonized by antibodies. As well, 
neutrophils can release cytokines and other cytotoxic proteins through 
degranulation, which may also recruit other immune cells to amplify the 
inflammatory response. Finally, neutrophils have recently been shown to create 
neutrophil extracellular traps to help kill microbes.6 Eosinophils are granulocytes 
which release various chemical mediators such as peroxidase, neurotoxin, 
ribonuclease, and major basic protein; growth factors; and cytokines.7 Basophils 
are granulocytes which release histamine, proteoglycans, and elastase and 
secrete various cytokines and lipid mediators.8 Mast cells are very similar to 
basophils, except are found in tissues rather than circulating in the blood. 
Monocytes are recruited to the site of infection and differentiate into either 
macrophages or DCs. They can also act as a professional antigen presenting 
cells (APC) through phagocytosis of infected cells and presentation of antigen to 
T cells. Macrophages phagocytose dying or dead cells and cellular debris 
containing microbes, which can then be presented to other immune cells. They 
can also secrete both pro- and anti-inflammatory cytokines, depending on the 
immune environment. DCs phagocytose microbes and present antigen to T and 
B cells in the lymph nodes. 
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1.1.2: Adaptive Immune System 
The innate immune system recognizes microbes through PRRs, which are not 
specific for a single antigen but rather a class of macromolecules. PRRs are 
unable to change or adapt to specific invaders, making the innate immune 
system fixed in what it can recognize.3 Unlike the innate immune system, the 
adaptive immune system can express a diverse repertoire of antigen specific 
receptors. T cells and B cells, which comprise the adaptive immune response, 
develop antigen specificity through somatic recombination in their T cell receptor 
(TCR) and B cell receptor (BCR) genes followed by two processes called positive 
and negative selection. Somatic recombination occurs during early lymphocyte 
development mediated by recombination activating genes 1 and 2. A single T cell 
or B cell can undergo multiple somatic recombination events of their TCR or 
BCR, respectively. After a recombination event, T cells undergo positive 
selection. Positive selection of T cells checks to be sure that these cells can 
recognize self-peptide on self-MHC, or, to put another way, these cells are MHC-
restricted to recognize only self-MHC. This process occurs in the thymus and is 
dependent on thymic stromal cells. Failure to pass the positive selection 
checkpoint leads to either another recombination event or death of the immature 
cell through lack of survival signals received. Following positive selection, these 
cells must pass another checkpoint called negative selection. Negative selection 
checks for the affinity between the TCR with self-peptide on self-MHC. This 
process also happens in the thymus, but is mediated mostly by bone marrow 
derived dendritic cells and macrophages. Thymic epithelial cells play less of a 
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role in negative selection. Those cells determined to have too high an affinity to 
self-antigen are induced to die in normal physiology. However, too high an affinity 
could lead to damaging autoreactivity. Cells that pass both positive and negative 
selection are then released into the periphery.9 Selection for B cells is different 
than that for T cells. Development and selection for B cells mostly occurs in the 
bone marrow. Positive selection for B cells does not require MHC at all but rather 
is dependent solely on the B cell itself. The BCR of B cells consists of two chains: 
a heavy chain and a light chain. In short, positive selection occurs when these 
two chains assemble a complex leading to signaling and proliferation. Negative 
selection against autoreactive BCRs is necessary as the recombination of the 
heavy and light chains are random. However, unlike with T cells, B cells that do 
not initially pass negative selection are not necessarily killed. Some of these 
autoreactive B cells can undergo a process called receptor editing in which the 
light chain is able to continue recombination until either a new, non-autoreactive 
receptor is made or until recombination events are exhausted. If the B cells are 
still autoreactive once recombination events are exhausted, most stop receiving 
survival signals and die. The autoreactive B cells that do not immediately stop 
receiving survival signals either become anergic or become clonally ignorant. 
Both of these processes begin in the bone marrow but finish in the periphery. 
Anergic B cells are no longer able to respond to antigen. Although these anergic 
cells are released from the bone marrow, they die in the periphery from lack of 
survival signals. Clonally ignorant B cells are self-reactive; however, they interact 
so weakly that little or no signally actually occurs. Alternatively, these clonally 
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ignorant B cells may not be encountering antigen due to the antigen not being 
available in the bone marrow or spleen.1,10  
 
There are two main subpopulations of T cells: CD4+ and CD8+ T cells. CD4+ T 
cells, or T helper cells (Th cells), help other immune cells primarily through 
release of various cytokines. These cytokines can either promote or suppress the 
immune response, depending on which cytokines are being produced. Naïve 
CD4+ T cells are activated through interaction with a peptide bound on MHC 
class II on APCs and an antigen non-specific co-stimulatory signal from the APC. 
These APCs also produce cytokines which help differentiate the CD4+ T cells 
towards a specific subtype, each with their own signature cytokine and 
transcription factor profile: type 1 T helper (Th1), Th2, Th9, Th17, regulatory T 
helper (Treg), and follicular T helper (Tfh) (Figure 1).11 CD8+ T cells, also referred 
to as cytotoxic T cells (CTLs), are specialized to recognize and kill tumor cells 
and cells infected by intracellular pathogens. CTLs kill through release of 
granules containing granzymes and perforin. To prevent non-specific killing, 
CTLs only release these cytotoxic granules after binding to the cell through 
creation of an immune synapse.12 Naïve CTLs are activated by TCR recognition 
of peptide antigen presented on MHC class I by APCs along with co-stimulatory 
signaling. As all nucleated cells in the body contain MHC class I, CTLs can 
recognize most cells in the body and kill infected cells as long as the peptide 
antigen is present on MHC class I.  
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Th1 cells are present during intracellular infections and during tumor growth. 
They are generated in the presence of IL-12. IL-12 signaling activates signal 
transducer and activator of transcription 4 (STAT4), which induces the Th1-
master transcription factor T-box transcription factor TBX21 (T-bet). Both STAT4 
and T-bet are required for optimal Th1 responses.13 Th1 cells produce both 
interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) for clearance 
of intracellular pathogens. If left uncontrolled, Th1 cells can cause autoimmune 
diseases and chronic inflammation. 
 
Th2 cells are essential in the resolution of extracellular pathogens. IL-4 signaling 
induces STAT6 activation, which promotes GATA binding protein 3 (GATA3) 
expression, the master transcription factor for Th2 cells. As well, thymic stromal 
lymphopoietin (TSLP) can help with Th2 differentiation through increased IL-4 
production.14 TSLP is not necessary for Th2 cell differentiation or function in 
already mature Th2 cells,15 but is important for their generation/maintenance in 
vivo.16 Th2 cells secrete IL-4, IL-5, and IL-13 as effector cytokines for elimination 
of extracellular pathogens. An uncontrolled Th2 response leads to allergic 
diseases. 
 
Th9 cells, like Th2 cells, help with eradication of extracellular pathogens, 
including helminths and parasites. Unlike Th2 cells, Th9 cells have been shown 
to be beneficial in preventing melanoma growth.17 These cells require 
transforming growth factor beta (TGF-β) and IL-4 for differentiation. This leads to 
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PU.1, interferon regulatory factor 4 (IRF4), and STAT6 activation and the 
subsequent production of predominately IL-9 and some IL-10 and IL-2.18 Like 
Th2 cells, Th9 cells contribute to allergic diseases if left unchecked.19 
 
Th17 cells help with pathogen clearance at mucosal surfaces and with anti-fungal 
response. They require TGF-β, IL-6, and IL-23 for their differentiation. These 
cytokines activate STAT3 signaling, leading to the expression of the master 
transcription factor retinoic acid receptor-related orphan receptor gamma t 
(RORγt). Once differentiated toward Th17, these cells begin to produce IL-17A, 
IL-17F, IL-21, and IL-22. Th17 cells also can contribute to various autoimmune 
diseases and glioma.20 
 
Tregs are critical for suppressing the immune response after clearance of 
pathogens and for maintaining tolerance to self-antigens. Tregs can be classified 
into two groups, depending on where they originate: natural or thymic Tregs 
(nTregs or tTregs) and peripheral or induced Tregs (pTregs or iTregs). nTregs 
develop in the thymus while pTregs develop extrathymically at peripheral sites.21 
While pTregs require the cytokine TGF-β for their differentiation, nTregs do not 
require TGF-β but seem to require IL-2/IL-15 signaling through CD122.22 IL-2 is 
also involved in maintenance of pTregs. Both require the master transcription 
factor for Tregs Forkhead box P3 (Foxp3). The regulatory function of Tregs is 
multifaceted; they use secretion of the cytokines IL-10 and TGF-β, cell contact-
dependent modulation and suppression, and cytolytic killing through granzyme or 
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perforin.23 Loss of Treg activity leads to fatal autoimmune disease while too much 
Treg activity leads to failure to clear pathogens and prevention of tumor 
clearance.  
 
Tfh cells help with humoral immunity through activating follicular B cells in 
secondary lymphoid organs. After follicular B cell and Tfh cell interaction, 
germinal centers are formed and maintained. CD40L on Tfh cells interacting with 
CD40 on follicular B cells and secretion of IL-4 and IL-21 by the Tfh cells help 
follicular B cells expand and differentiate into both plasma cells and memory B 
cells. Tfh cells require IL-6 and IL-21 for their differentiation, leading to the 
activation of multiple STAT proteins with STAT3 being the most important.24 
Activation of these STAT proteins leads to B cell lymphoma 6 (Bcl6) expression, 
the master transcription factor for Tfh cells. An abnormal Tfh response can cause 
B cells to produce autoreactive antibodies leading to autoimmune disease. 
 
The B cell component of the adaptive immune system is responsible for the vast 
majority of the humoral immune response. Naïve B cells are activated upon 
antigen binding to BCR. While both T and B cells can recognize peptides, B cells 
can also recognize unprocessed proteins, glycoproteins, and polysaccharides. 
Also like T cells, B cells require a secondary signal to become fully activated. The 
secondary signal can come from T cells through CD40L/CD40 interaction and is 
called T cell-dependent activation. The secondary signal can also come from the 
antigen itself through recognition of a common microbial constituent or through 
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cross-linking of multiple BCR to repeating epitopes. This is called T cell-
independent activation.1 BCR binding and secondary signaling leads to B cell 
proliferation and differentiation. After activation some B cells undergo 
immunoglobulin (Ig) class switching. Naïve mature B cells express IgM and IgD 
subclasses at first, but after activation can switch to expressing IgG, IgE, or IgA 
subclasses, each with a distinct effector function. Which Ig subclass the B cell 
will switch to depends on the cytokine environment in which the B cell is located. 
The variable regions of the antibody do not change, only the constant region of 
the Ig heavy chain, ensuring antigen specificity remains. Along with Ig class 
switching, activation of B cells causes them to undergo affinity maturation. This 
involves mutations in the variable regions of IgM, IgG, IgA, and IgE antibodies to 
increase affinity toward an antigen in processes called somatic hypermutation 
and clonal selection. This ensures that only B cells with the highest affinity 
toward an antigen survive. Those that do survive produce highly efficient 
antibodies that bind a specific antigen for neutralization and elimination.25 
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Figure 1. Th cell differentiation 
After TCR activation naïve CD4+ T cells begin differentiation based on the 
cytokine milieu encountered. These cytokine milieus activate specific 
transcription factors leading to the differentiation of various Th cells subsets. 
Each subset has specific transcription factors, chemokine receptors, and 
cytokines produced leading to unique immune function for each subset to help 
against microbe invasion. Immune pathologies occur when a specific subset is 
allowed uncontrolled differentiation. 
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1.2: ST2 
In 1989, the Il1rl1 gene product, given the name ST2 and later defined as the IL-
33 receptor, was discovered.26,27 It belongs to the IL-1-receptor superfamily. 
Some literature misnamed ST2 as “suppressor of tumorigenicity 2”, when in fact 
the original name was “growth stimulation expressed gene 2”.27 ST2 has recently 
been renamed by the original discoverer, Shin-ichi Tominaga, as “serum 
stimulation-2”,28 as it was first discovered to function as a mediator of type 2 
inflammatory responses.29 IL1RL1 is located on chromosome 2q12.1 in humans, 
while the gene “suppressor of tumorigenicity 2”, also called ST2, is located on 
chromosome 11p14.3-p12 in humans. 
 
ST2 has two main splice variants due to differential promoter usage: a 
membrane bound form (ST2), which promotes NF-κB signaling, and a soluble 
form (sST2), which prevents its signaling. It was not until 2005 that the ligand for 
ST2, the cytokine IL-33, was identified through database searching for genes 
homologous to other IL-1 superfamily members.30,31 IL-33 has been identified as 
a mediator of various inflammatory diseases such as asthma, cardiovascular 
diseases, and allergic diseases.31 Besides being secreted, IL-33 can be found in 
the nucleus of human high endothelial venules,32 lung airway epithelium, 
keratinocytes, fibroblastic reticular cells, and some epithelial cells of the stomach 
and salivary glands.33 Due to the presence of a N-terminal domain nuclear 
localization sequence and a homeodomain-like helix-turn-helix motif, IL-33 is 
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able to bind heterochromatin, potentially giving IL-33 transcriptional regulatory 
capacity.32 
 
Dysregulation of IL-33/ST2 signaling and sST2 production have been implicated 
in a variety of inflammatory diseases such as cardiac disease,34-37 intestinal 
bowel disease (IBD),38-41 graft-versus-host disease (GVHD),42-49 small bowel 
transplant rejection,50 and type-2 diabetes.47,51-53 
 
1.2.1: Two main isoforms of ST2  
The ST2 gene is located on human chromosome 2q12.1 and is approximately 40 
kb long. Homologues of ST2 are found in the genomes of mouse, rat, and fruit 
fly. ST2 has four splice isoforms from a single transcript dependent on the 
promoter being used: ST2, a membrane receptor; sST2, a soluble factor; ST2V, 
a variant form of ST2, and ST2LV, another variant form of ST2, which are 
differentially regulated through alternative promoter usage.54-56 Little is known 
about ST2V other than it is expressed highly in gastrointestinal organs.57 ST2LV 
lacks the transmembrane domain found in ST2, is secreted by eye, heart, lung, 
and liver tissues, and is found during later stages of embryogenesis.58 Other 
information on ST2LV is currently lacking. 
 
By cloning the Il1rl1 gene in rat and sequencing sST2 and ST2 cDNAs, it was 
found that sST2 and ST2 have different exon 1 sequences.54 Mapping the 
promoter regions for Il1rl1 showed that the transcription start site for sST2 is in a 
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proximal promoter region while the transcription start site for ST2 is in a distal 
promoter region, 15kb upstream from the sST2 proximal promoter (Figure 2).54  
Three to four GATA transcription factors have been identified at the distal 
promoter region within 1001 bp, two of which were conserved between human 
and mouse Il1rl1 genes.56,59 These GATA elements binding to the distal promoter 
lead to ST2 expression. The transcription factor PU.1 also binds to the distal 
promoter near the GATA elements in both human mast cells and basophils.60 
PU.1 and GATA2 cooperatively transactivate the distal ST2 promoter inducing 
expression of ST2, but not sST2.60 Loss of PU.1 significantly decreased ST2 
expression.60 Conversely, a PMA-responsive element has been found near the 
proximal promoter region of ST2 in the mouse fibroblast line NIH 3T3.61 Similarly, 
activating the human fibroblast line TM12, which only uses the proximal promoter 
for Il1rl1 transcription, led to sST2 expression.56 These data further suggest that 
the distal promoter is used to transcribe ST2 and the proximal promoter is used 
to transcribe sST2. These results indicate key transcription factors important in 
ST2 or sST2 expression; however, ChIP-seq experiments have yet to be 
performed.  
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1.2.2: Membrane ST2 
ST2 was first found in serum-stimulated BALB/c-3T3 cells in the presence of 
cycloheximide.62 It contains an extracellular domain, which binds IL-33 with the 
help of IL-1 receptor accessory protein (IL-1RAP), a transmembrane domain, and 
an intercellular domain called a Toll/Interleukin-1 receptor (TIR) domain. Due to 
the presence of the TIR domain, ST2 has been classified as a member of the IL-
1 receptor superfamily. ST2 is expressed on cardiomyocytes63 and a large 
variety of immune cells, including T conventional cells, particularly type 2,64 T 
regulatory cells (Tregs),65 innate helper 2 cells (ILC2),66 M2 polarized 
macrophages,67 mast cells,68 eosinophils,69 basophils,70 neutrophils,70 NK,71 and 
iNKT cells.71 Signaling through ST2 in immune cells induces type-2 and Treg 
immune responses, IgE production, and eosinophilia.30,64-66,72 
 
1.2.3: Soluble ST2 
sST2 protein lacks the transmembrane and cytoplasmic domains contained on 
ST2 and contains a unique nine amino-acid C-terminal sequence.59 In vitro, sST2 
production has been shown to be enhanced by proinflammatory cytokines (IL-1β, 
TNF-α) in human lung epithelial cells and cardiac myocytes. In humans, sST2 
can be produced spontaneously by cells in the lung, kidney, heart, small 
intestine,73 but can also be produced after activation with IL-33 in mast cells74 or 
anti-CD3/anti-CD28 in both CD4 and CD8 conventional T cells.75 In a murine 
aGVHD model, it has recently been shown that intestinal Th17 and Tc17 cells 
produced large amounts of sST2 following alloreactivity.75 This enhanced sST2 
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presence has been shown to inhibit the production of the type 2 cytokines IL-4 
and IL-5 but not the type 1 cytokine IFN-γ.76 
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Figure 2. Different promoter usage dictates ST2 and sST2 expression  
ST2 consists of two main isoforms: ST2 and sST2. These isoforms are splice 
variants of each other regulated by alternative promoter bindings, the distal 
promoter for ST2 and the proximal promoter for sST2. Exon 1 varies between 
ST2 and sST2 depending on the promoter being bound. In immune cells GATA1, 
GATA2, and PU.1 have been shown to bind to the distal promoter. The proximal 
promoter has not been as well studied; however, a PMA-responsive element has 
been shown to induce sST2 transcription.  
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1.3: IL-33/ST2 signaling 
1.3.1: The membrane bound form of ST2 signals through MyD88/NF-κB 
Upon IL-33 binding, the membrane-anchored ST2 forms a heterodimer along 
with IL-1RAP77,78 leading to the dimerization of the TIR domain. This leads to the 
recruitment of the TIR domain binding protein MyD88 and subsequent IL-1R-
associated kinase (IRAK) activation, which can activate MAP kinases and NF-κB 
pathways (Figure 3).30,31 In regards to IL-33/ST2 signaling, how IL-33/ST2 
signals specifically to either the MAPK or NF-κB is currently unclear. However, 
downstream events of ST2 do seem to occur differentially, as TRAF6 is required 
for NF-κB activation and induction of type 2 cytokines but TRAF6 is not needed 
for IL-33 induced ERK (a MAPK protein) activation.79 How TRAF6 independent 
activation of ERK occurs after IL-33 binding ST2 is currently unknown. 
 
A recent report has shown that signaling through IL-33/ST2 in colonic Tregs 
helps to promote Foxp3 and GATA3 expression while also promoting Treg 
function through enhancing TGF-β1-mediated differentiation.65 This 
enhancement is caused by phosphorylation of GATA3, which leads to more 
GATA3 and RNA polymerase II binding to the Foxp3 promoter.65 GATA3 binds to 
and activates the ST2 promoter, enhancing ST2 on the surface of both Th2 
cells80,81 and Tregs.65,81 IL-33 has been shown to drive NF-κB and p38 signaling 
in Tregs, leading to the selective expansion of ST2+ Tregs.82 As this effect is 
observed in Tregs in a non-diseased setting, independent of outside 
inflammatory responses, we believe the IL-33/ST2-GATA3-Foxp3 pathway to be 
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canonical. Conversely, in a non-canonical MyD88 dependent pathway,83 IRF1 
signaling can inhibit Tregs by binding to the Foxp3 promoter and preventing 
Foxp3 transcription in murine T cells;84 however, this signaling leading to IRF1 
activation through MyD88 has only been shown to be induced using CpG-B, a 
TLR9 agonist and a pathway independent from IL-33/ST2.83 Whether IL-33/ST2 
can activate IRF1 in a MyD88-dependent pathway and whether this IL-33/ST2-
IRF1 activation can affect Treg function is currently unknown. 
 
Unlike IL-1RAP, the single immunoglobulin domain IL-1R-related molecule 
(SIGIRR or TIR8) SIGIRR can form a complex with ST2 upon IL-33 stimulation 
and can inhibit IL-33/ST2-mediated signaling both in vitro and in vivo.31,85 IL-33 
binding to ST2 has also been shown to negatively regulate ST2 through protein 
polyubiquitination, internalization, and degradation.86 
 
1.3.2: The soluble form, (s)ST2, is a decoy receptor and does not signal 
sST2 acts as a decoy receptor to sequester free IL-33, preventing IL-33/ST2 
signaling. This was shown using a thymoma cell line transfected to express ST2, 
but not sST2, in the presence of added IL-33. When these thymoma cells were 
pre-treated with sST2, they showed suppressed NF-κB activity.87 Another group 
used IL-33-treated cardiomyocytes and observed blocked pro-hypertrophic 
effects of angiotensin II or phenylephrines in the presence of sST2.88 Blocking 
NF-κB signaling in lung alveolar epithelial cells and cardiac myocytes with the 
specific NF-κB inhibitor CAPE prevented sST2 production by these cells.73 In a 
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human endotoxin model, healthy donors injected with LPS (2 ng/kg) had 
increased sST2 in their plasma within 24 hours of injection.73 Fibroblast growth 
factor 2 enhanced sST2 production in the human breast adenocarcinoma cell line 
MCF-7 through MEK/ERK signaling.89 Lysophosphatidic acid has also been 
shown to increase sST2 production by human bronchial epithelial cells in an NF-
κB or JNK-dependent manner.90 Enhanced sST2 plasma circulation has been 
correlated with pulmonary fibrosis,91 acute myocardial infarction,63 subclinical 
brain injury and stroke,92 celiac disease,93 gastric cancer,94 HBV-related acute-
on-chronic liver failure,95 HIV progression,96 and GVHD.42-49 
 
1.3.3: IL-33 regulation and release 
IL-33 is expressed mainly by nonhematopoietic cells, including endothelial cells, 
adipocytes, fibroblasts, and intestinal and bronchial epithelial cells;33,97,98 
however, some hematopoietic cells like dendritic cells have also been shown to 
express IL-33 when activated.30 In many nonhematopoietic tissues, IL-33 is 
constitutively expressed. Constitutive expression of IL-33 in epithelial cells 
suggests that IL-33 is used as an alarmin in response to infection or injury.33 An 
alarmin is an endogenous molecule that is constitutively available and released 
when tissue is damaged. Upon release, an alarmin helps activate the immune 
system. Further suggesting IL-33 is an alarmin, IL-33 is released by damaged or 
necrotic cells,33 leading to activation of the immune system through IL-33/ST2 
signaling.33,99 
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During homeostasis IL-33 is found primarily in the nucleus due to a nuclear 
localization sequence in the N-terminus, leading to binding of heterochromatin in 
the nucleus.32 Nuclear IL-33 can bind directly to NF-κB, sequestering it and 
preventing NF-κB signaling in HEK293RI cells, causing a downregulation of 
proinflammatory signaling.100 Further evidence of IL-33 having the ability to 
repress gene transcription is described because there is a structural similarity 
between a part of the IL-33 protein and the Kaposi sarcoma herpes virus motif 
latency-associated nuclear antigen.100 This homology suggests that IL-33 can 
bind to the H2A-H2B chromatin dimer and regulate the compaction of chromatin 
through nucleosome-nucleosome interactions. Recent discoveries have shown 
that nuclear IL-33 can bind to multiple sites in the promoter regions of ST2 in 
human endothelial cells and that knockdown of IL-33 increased sST2 levels.101 
Loss of the nuclear localization domain of IL-33 led to non-resolving lethal 
inflammation.102 However, IL-33-/- mice fail to develop autoimmune disease, and 
no one has shown whether nuclear IL-33 has been found in immune cells. These 
results indicate that nuclear IL-33 could act as a moderator of inflammation, but 
more evidence is needed to confirm the extent of the ability of nuclear IL-33 to 
moderate inflammation.  
 
During cell stress or damage, IL-33 is passively released from the nucleus in full-
length form and can bind to ST2, leading to activation of the IL-33/ST2 pathway. 
Like other IL-1 superfamily members, IL-33 can be cleaved at the N-terminus to 
enhance its biological activity. Unlike other IL-1 superfamily members, however, 
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IL-33 is not cleaved via caspases.103,104 Surprisingly, caspase-1, caspase-3, or 
caspase-7 processing actually leads to IL-33 inactivation.105,106 Inactivation of IL-
33 via caspases is therefore thought to alleviate the immune response, rather 
than enhance it. Other proteins are able to cleave released IL-33, such as the 
neutrophil serine proteases cathepsin G and elastase, mast cell derived serine 
proteases, tryptase, and chymase. These proteins, unlike caspases, increase the 
biological activity of IL-33 by 10 to 30 times compared to that of full length IL-
33.104,107,108  
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Figure 3. IL-33/ST2 signaling pathway 
IL-33 either binds to the ST2/IL1RAP heterodimer, recruiting MyD88 to its 
intracellular domain, or the sST2 decoy receptor, which does not signal. MyD88 
binding recruits IRAK and TRAF6, leading to either the NF-κB or AP-1 pathways 
being activated. NF-κB and AP-1 activation promote inflammatory cytokine 
expression. On Tregs, IL-33/ST2 signaling has been shown to promote the 
expression of Foxp3 and GATA3 while also promoting Treg function and 
expansion through enhancing TGF-β1-mediated differentiation though a p38-
dependent mechanism. 
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1.4: ST2 signaling in lymphoid cells 
1.4.1: Th2 cells 
ST2 was first shown both in vitro and ex vivo to be preferentially expressed on 
murine Th2 cells (Figure 4) expressing predominantly IL-4, IL-5, or IL-10, but not 
IFN-γ or IL-2.64,109 Its expression is independent of IL-4, IL-5, and IL-10, as loss 
of any of these cytokines does not affect ST2 expression on Th2 cells.64 ST2 
expression on Th2 cells is dependent on GATA3 signaling110 and is enhanced by 
IL-6, IL-1, TNF-α, and IL-5.29 Given that ST2 expression in Th2 cells is 
independent of IL-4 and dependent on GATA3 signaling, it makes sense that 
ST2 expression occurs late during Th2 differentiation.29 IL-33 stimulation of Th2 
cells in vitro increased the amount of IL-5 and IL-13 produced.30 Antigen-specific 
ST2+ Th2 cells were shown to produce more IL-5 and IL-13 compared to non-
antigen-specific Th cells and ST2-/- Th2 cells.111 Interestingly, IL-33 polarization 
of antigen stimulated murine and human naïve CD4+ T cells leads to high IL-5 
production but no IL-4 production, independent of GATA3 and STAT6 induction 
but dependent on MAPK and NF-κB signaling.86,112 Adoptive transfer of these 
cells into naïve IL-4-/- mice still triggered airway inflammation.112 In vivo 
administration of IL-33 led to an increase in the number of lymphocytes 
circulating in the blood and increased type 2 cytokine secretion in the thymus, 
spleen, liver, and lung.30 IL-33 has also been shown to be a chemoattractant for 
Th2 cells, as adoptive transfer of Th2 cells into Il1rl1-/- mice followed by IL-33 
administration into the footpad of these mice led to the accumulation of the 
transferred Th2 cells.113 Loss of ST2 on Th2 during infection with the helminthic 
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parasite Nippostrongylus brasiliensis did not affect Th2-mediated clearance of 
the infection, nor was recruitment of Th2 cells in a murine model of asthma 
dependent on ST2 indicating that ST2 is not necessary for Th2 function.114 
Recently, it was shown that human and murine Th2 cells do not produce sST2 in 
vitro.75  
 
1.4.2: Th9 cells  
IL-9-producing Th9 cells are the newest T cell subset to be described, polarized 
through TGF-β and IL-4 signaling.115,116 When used separately on naïve T cells, 
TGF-β alone would cause Treg development, while IL-4 would induce Th2 cell 
differentiation. It has been found that the PU.1 gene is a Th9-specific 
transcription factor, which could induce IL-9 production in cells under Th2- or 
Th9-stimulating condition in vitro.117 Human or mouse PU.1-deficient T cells have 
diminished IL-9 production. Furthermore, IRF4 binds directly to the IL-9 promoter, 
and is required for the development of Th9 cells, similar to PU.1.118 However, 
unlike PU.1, IRF4 is also required for the development of other Th cell subsets, 
including Th2 and Th17 cells.119,120 Studies have shown that Th9 cells primarily 
secrete IL-9 to mediate the immune response in several diseases, such as 
asthma, autoimmune diseases, and parasitic infections,121 and IL-9 is associated 
with impaired Th1 immune response in patients with tuberculosis.122 Treatment of 
in vitro polarized human Th2 cells with TGF-β and IL-33 increases expression of 
IL-9 and ST2.123,124 
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1.4.3: Tregs 
IL-33/ST2 signaling in Tregs was first suggested to enhance their protective 
ability in an experimental colitis model in which IL-33 treatment ameliorated 
colonic tissue injury and colitis symptoms.65 IL-33 was shown to increase both 
ST2 and Foxp3 levels and expand Tregs in mice with colitis. IL-33/ST2 signaling 
in Tregs has also been shown to increase Treg frequency and decrease IL-17 
and IFN-γ production in an EAE model.24,125 ST2+ Treg expansion is helped by 
IL-33 signaling in dendritic cells, as IL-33 has been shown to stimulate dendritic 
cell production of IL-2 which selectively expands ST2+ Tregs.126 In a model of 
aGVHD, treatment of mice daily with IL-33 from 10 days pre-transplantation to 
day 4 post-transplantation enhanced their frequency of ST2+ Tregs, which 
persisted after irradiation, leading to disease amelioration through prevention of T 
conventional cell accumulation in target aGVHD organs.82 Treatment of mice 
receiving a heart transplant with IL-33 prolonged graft survival through increased 
Treg and myeloid derived-suppressor cell numbers.127,128 Similarly, mice treated 
with IL-33 after skin transplantation had increased Treg numbers in the graft, 
decreased IFN-γ and IL-17 production, increased IL-10 production, and 
increased skin graft survival.129 This group also showed that IL-33/ST2 signaling 
can convert Foxp3- CD4 cells into Foxp3+ CD4 Tregs in the periphery. We have 
shown that in a murine model of allogeneic hematopoietic stem cell 
transplantation HCT, transplanting Il1rl1-/- Tregs with WT T conventional cells 
worsens aGVHD compared to mice receiving WT T conventional cells and 
Tregs,75 further indicating the enhanced suppressive effect of ST2+ Tregs. 
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Conversely to the enhanced protective effect of Tregs through IL-33/ST2, it has 
been reported that IFN regulatory factor 1 (IRF1) is downstream of MyD88130 and 
negatively regulates Foxp3 transcription,84,130 although whether or not IL-33/ST2 
signaling increases IRF1 expression, leading to decreased Treg function, has yet 
to be studied. These data show that IL-33 signaling on Tregs increases their 
immunomodulatory function and could be further studied for their potential clinical 
benefits in a variety of diseases. 
 
1.4.4: Innate lymphoid cells type 2 (ILC2s) 
ILC2 cells were first discovered in the mouse and human fat-associated lymphoid 
clusters located in the mesentery. These cells were found to be lineage marker 
negative, c-Kit positive, Sca-1 positive, IL-7Rα positive, and ST2 positive.66,131 
These cells have been shown to play a protective role against helminth infection 
and regulate metabolic homeostasis.132 In humans ST2+ ILC2s were later found 
in the lung and gut133 and these ILC2s produced IL-5 and IL-13. During ILC2 
activation ST2 is upregulated in a GATA3 and Gfi1-dependent manner.134,135 
Treatment of Rag2 KO mice with IL-33 induced IL-5 and IL-13 production, 
whereas Rag2 and common gamma chain double KOs, which still have mast 
cells and basophils (both of which express ST2 and secrete type 2 cytokines), 
did not increase IL-5 or IL-13 production, indicating that this increase is due to 
ILC2 stimulation with IL-33.66 IL-33/ST2 signaling enhancement was shown to 
expand ILC2s in vivo.66,136 This group also found that ILC2s are major producers 
of type 2 cytokines after Nippostrongylus brasiliensis infection. It was also shown 
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using the N. brasiliensis infection model that loss of both IL-33 and IL-25 
signaling on ILC2s completely abrogated the early response against this infection 
due to impaired expansion of ILC2s and lack of IL-13 production and adoptive 
transfer of WT ILC2s rescued this phenotype.66 During lung inflammation ILC2s 
produce IL-9,137 and IL-33 can promote cytokine production by ILC2s.138 
Recently, it was shown that in a murine eosinophilic airway inflammation model 
that T-bet regulates IL-9 production by IL-33-stimulated ILC2s.139 IL-33/ST2 
signaling in ILC2s is also important for protection against lung infection, as 
blocking ST2 signaling during influenza infection in mice lowered ILC2 frequency 
and number in the lung, and resulted in diminished lung function, loss of airway 
epithelial integrity, and impaired respiratory tissue remodeling.140 Histological 
examination of influenza-infected lungs from anti-ST2 treated mice showed 
severe damage similar to that seen in a similar experiment where ILC2s were 
depleted.140 ILC2s have been recently reported to home to the skin in humans, 
where activation induces upregulation of ST2.138 IL-33/ST2 signaling of ILC2s in 
the murine skin has been shown to promote atopic dermatitis-like 
inflammation,138,141 but also promote skin wound repair.142 However, 
overstimulation of ILC2s with IL-33 during tissue remodeling of the liver after 
chemical injury promoted liver fibrosis.143 Also, signaling through IL-33/ST2 on 
ILC2s during breast cancer has been shown to promote breast cancer growth 
and metastasis.144 These data indicate that beneficial or harmful IL-33/ST2 
stimulation in ILC2s is dependent on certain disease states.  
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1.4.5: CD8 T cells 
CD8 T cells have been shown to either express ST2 or produce sST2.75,80,145 
Although CD8 T cells express low levels of ST2, loss of either IL-33 or ST2 
impaired the CD8 T cell response to lymphocytic choriomeningitis virus (LCMV) 
infection.145 IL-33/ST2 signaling has also been shown to enhance CD8 T cell 
antitumor activity.146 During aGVHD, however, IL-33 treatment during peak 
inflammation significantly increased aGVHD severity and mortality in part through 
increased expansion of Tc1 cells.121 Given that IL-33 can increase type 1 
responses when IL-12 levels are high,147 IL-33 treatment during peak 
inflammation was deleterious in this case. 
 
1.4.6: B cells 
ST2 has been shown to be expressed on B1 B cells but not B2 B cells, leading to 
enhanced proliferation capacity and IgM, IL-5, and IL-13 production both in vitro 
and in vivo; neutralizing IL-5 almost completely abolished this effect.148 Recent 
studies have also shown that IL-33 treatment in mice increases circulating IL-10-
producing B cells that are neither conventional B1 or B2 B cells.149 Adoptive 
transfer of these IL-33-treated, IL-10 producing B cells prevented spontaneous 
colitis in IL-10-/- mice without affecting Treg frequency.149  
 
1.4.7: iNKT cells and NK cells 
IL-33/ST2 signaling in murine iNKT cells causes their expansion and 
activation.150 Mice treated with IL-33 had twice as many iNKT cells in the spleen 
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and liver compared to untreated mice.150 Unexpectedly, ST2 signaling in iNKT 
cells induced IFN-γ instead of IL-4 upon TCR engagement, which synergized in 
the presence of IL-12.71,150.This effect was also seen in Vα24+ human iNKT 
cells.71 NK cells constitutively express ST2 and IL-33/ST2 signaling increases 
IFN-γ levels synergistically with IL-12.71,150 Loss of ST2 in Ly49H+ NK cells did 
not affect their development but did impair their ability to expand and protect 
against MCMV.151 These data have not yet been translated to human disease. 
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Figure 4. IL-33 signaling in immune cells  
Tissue damage and mechanical stress to epithelial, endothelial, and stromal cells 
leads to the release of IL-33 from these cells. IL-33 then signals through many 
different immune cells, enhancing their function.   
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1.5: sST2 expression in lymphoid cells 
1.5.1: Th1 and Th17 cells 
Although much of the research on IL-33/ST2 signaling in T conventional cells has 
been devoted to type 2 signaling, recent studies have come out on IL-33/ST2 
signaling in type 1 and type 17-mediated diseases. Blockade of IL-33 with 200 μg 
anti-IL-33 every other day from day 0 until day 18 post-MOG35-55 injection during 
MOG-induced experimental autoimmune encephalomyelitis (EAE) ameliorated 
the disease in part through decreased IL-17 and IFN-γ production, and treatment 
of 50 μg/kg IL-33 during this same time course enhanced IL-17 and IFN-γ 
production.24 However, the amount of IL-33 given here is not physiological, so 
caution must be advised when interpreting this data. Conversely, another group 
using the same EAE model found that treatment with 1 μg IL-33 daily from day 
12 to day 20 after immunization reduced IL-17 and IFN-γ production and 
alleviated the disease.125 Seemingly, the timing of IL-33/ST2 treatment affects 
response, perhaps through differing environments. In a murine model of 
collagen-induced arthritis, treatment with anti-ST2 antibody reduced both IFN-γ 
and IL-17 production.152 In a murine model of rheumatoid arthritis, treatment with 
an sST2-Fc fusion protein attenuated disease and decreased production of IFN-
γ, TNF-α, and IL-6.153 Recently, we were the first to show that both murine and 
human Th1 and Th17 cells produce sST2 in vitro and in vivo after HCT.75 
Blocking ST2 with a blocking antibody in vivo decreased sST2 production in 
intestinal T cells 10 days after HCT while maintaining ST2. Recipients of ST2-/- T 
cells, compared to WT T cells, showed lower frequencies of Th1 and Th17 cells 
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and higher frequencies of Th2 and Treg cells.75 Importantly, anti-ST2 treatment 
did not lead to loss of immunomodulatory ST2+ Tregs but rather maintained them 
in the intestine. Based on our findings, we have suggested that increased sST2 
production affects the normal balance of pathogenic Th1/Th17 cells and 
immunomodulatory Th2/Treg cells by promoting the Th1/Th17 response and 
dampening the ST2-mediated Th2/Treg response through sequestering IL-33.75  
 
1.5.2: Tc1 and Tc17 cells 
We were also the first to demonstrate that CD8 T cells, particularly Tc1 and Tc17 
cells but not Tc2 cells, produce significant amounts of sST2 in vitro and after 
HCT due to alloreactivity.75 sST2 secretion by donor T cells significantly 
increased as aGVHD progressed. Similarly to CD4 T cells, blocking ST2 with a 
blocking antibody decreased sST2 production by Tc1 and Tc17 cells in vivo after 
HCT.75 Our data indicates that sST2 secretion by Tc1 and Tc17 cells sequesters 
free IL-33, preventing IL-33/ST2-mediated Th2/Treg responses. In patients with 
early HIV infection, sST2 levels were strongly correlated with CD8 T cell count 
and their expression of the activation markers HLA-DR and CD38.96 However, it 
is not known if sST2 was produced from the CD8 T cells themselves or if sST2 is 
only a marker of gut damage and disease progression. While our study was the 
first to show that preventing sST2 secretion from CD8 T cells prevented disease 
pathogenesis, further studies are warranted to determine their role in other 
disease pathogeneses. 
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1.6: Myeloid cells 
1.6.1: Macrophages 
Macrophages, mast cells, basophils, eosinophils, and dendritic cells all have 
been shown to express ST2.67-70,154 IL-33 amplifies the expression of M2 markers 
on murine macrophages.67,155 Bone derived human macrophages have been 
shown to constitutively express both ST2 and sST2; however, skewing these 
macrophages toward an M2 phenotype using IL-4 and IL-13 increased the 
expression of ST2 while not affecting sST2 expression.156 IL-33/ST2 signaling 
has been shown to enhance the activation of macrophages by upregulating the 
LPS receptor components TLR4 and MD2, soluble CD14, and MyD88.155 
 
1.6.2: Mast cells 
IL-33/ST2 signaling on both murine and human mast cells has been shown to 
promote their survival in the peritoneum through upregulation of B-cell 
lymphoma-X large (Bcl-xL).157 IL-33/ST2 signaling also promotes mast cell 
activation and maturation, as IL-33 treatment of CD34+ mast cell precursors 
accelerated their maturation in vitro and induced GM-CSF, IL-5, IL-13, CXCL8, 
CCL17, CCL22, and CCL2 secretion.158,159 These cytokine and chemokine 
secretions may be NFAT and AP-1 signaling-dependent.160 It is well documented 
that mast cells can produce a variety of type 2 cytokines after ST2 
signaling;24,161,162 however, IL-33/ST2 signaling on mast cells during airway 
inflammation has also been shown to promote a Th17 response.60  
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1.6.3: Basophils and Eosinophils 
IL-33/ST2 signaling in basophils promotes not only type 2 cytokine secretion 
such as IL-4 and IL-13 but also IL-8 in synergy with IL-3 or Fcε receptor 
activation.163 Basophils can also release sST2 after activation via IL-3 and C5a or 
anti-FcεRIα antibody, while IL-33 prevents sST2 release.163 IL-33 induces the 
degranulation of eosinophils and production of superoxide,69 controls their 
responsiveness to Siglec 8,24 and increases IL-13, TGF-β, CCL3, CCL17, and 
CCL24 in the lungs during airway inflammation.164 Treatment with anti-ST2 
antibodies prevented the upregulation of CD11b and also decreased the survival 
of eosinophils.70 
 
1.6.4: Dendritic cells 
Dendritic cells (DCs) express low basal levels of ST2 on their cell surface;154 
however, activation of DCs with rapamycin strongly upregulates ST2 through 
autocrine IL-1β signaling.165 Treatment of DCs with IL-33 has been shown to 
increase surface levels of MHC-II, CD40, CD80, CD86, OX40L, and 
CCR7.35,154,166 IL-33/ST2 signaling in DCs also increases their production of IL-4, 
IL-5, IL-13, CCL17, TNF-α, and IL-1β.35 In the presence of naïve CD4+ T cells, 
IL-33-activated DCs induce IL-5 and IL-13 but not IL-4 and IFN-γ from the T 
cells.154,166 Interestingly, sST2 has also been shown to be internalized by DCs, 
suggesting a non-canonical method of action for sST2 besides sequestering free 
IL-33.167 It is currently unknown what internalization of sST2 by DCs means and 
whether sST2 can be internalized by other immune cells. IL-33-activated murine 
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DCs have recently been shown to be required for in vitro and in vivo expansion of 
ST2+ Tregs through DC IL-2 production,126 which could be used for therapeutic 
benefit against inflammatory diseases through expansion of Tregs both in vitro 
and in vivo. ST2 expression on host hematopoietic cells, including DCs, and non-
hematopoietic cells was not implicated in the severity of aGVHD as recipient ST2 
knockout (KO) bone marrow chimera did not modify aGVHD severity.75 
 
1.6.5: Neutrophils 
While ST2 has been shown to be present on neutrophils,70,168 not much is known 
about the role of ST2 on neutrophils. Activation of TLR4 on neutrophils leads to 
downregulation of CXCR2, which is important for their recruitment to sites of 
infection; however, IL-33-treated murine and human neutrophils do not 
downregulate CXCR2 after TLR4 activation by inhibiting GRK2.168 IL-33 injected 
into the ears of mice induced neutrophil recruitment to the skin;169 however, it is 
not clear if IL-33/ST2 signaling on the neutrophils directly led to their migration. 
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1.7: IL-33/ST2 in intestinal diseases 
1.7.1: Inflammatory bowel disease 
It is believed that inflammatory bowel disease (IBD) starts with a dysregulated 
immune response to either food or commensal gut bacteria, leading to the 
production of proinflammatory cytokines such as TNF-α, IL-6, IL-1, and IL-8. 
Expression of these cytokines along with chemokine release leads to attraction of 
T cells, specifically type 1 T cells, to the intestines. Continual damage of the gut 
mucosa by these type 1 cells and other immune cells such as macrophages, 
neutrophils, and dendritic cells leads to the release of various alarmins and other 
proteins. sST2 was found to be significantly increased in both the gut mucosa 
and serum in both patients and experimental models of IBD.38-41 However, in IBD 
patients, ST2 expression in the colonic mucosa remained similar to that of 
healthy patients.38 In the lamina propria of active ulcerative colitis (UC) patients, 
ST2 predominately came from CD11b+ and CD4+ cells.39 These findings suggest 
that increased sST2 production by lymphocytes or the gut mucosa could either 
lead to development of IBD, particularly UC, or that these proteins are markers 
for disease severity.  
 
IL-33/ST2 signaling has been shown to enhance epithelial proliferation and 
mucus production in the gut,30 suggesting that the increase in IL-33 in the colonic 
mucosa in active UC could be beneficial. However, in multiple mouse models of 
IBD, use of Il1rl1-/- mice led to amelioration of IBD compared to wild type (WT) 
controls. These results were verified using an IL-33 KO. Using bone marrow 
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chimeras, it was shown that ST2 signaling in non-hematopoietic cells was 
responsible for IBD. This was due to IL-33/ST2 signaling impairing epithelial 
barrier function and delayed wound healing. Lack of ST2 signaling in 
hematopoietic cells did not prevent UC development. A ST2 blocking antibody 
confirmed the findings from the KO experiments.170 Crohn’s disease (CD), 
however, shows opposite results from UC. In a trinitrobenzene sulfonic acid 
(TNBS)-induced experimental colitis murine model, which mimics human CD, 
administration of recombinant IL-33 (rIL-33) ameliorated colonic tissue injury and 
clinical symptoms of colitis.80 Protection was shown to be through upregulation of 
type 2 cytokines, Foxp3+ T regulatory cells (Tregs), and CD103 dendritic cells, 
which promote Treg development. In patient colons with active IBD, Treg levels 
in the lamina propria are increased compared to healthy controls and function 
normally.171,172 It has recently been shown that colonic Tregs preferentially 
express ST2 and that signaling through IL-33/ST2 both promotes Treg 
accumulation and maintenance in the intestine and enhances their protective 
function.65 However, treatment with rIL-33 to promote Treg-mediated protection 
may be time-dependent, as rIL-33 treatment at onset of a DSS-induced colitis 
model exacerbated disease severity. rIL-33 treatment during recovery or chronic 
phases ameliorated DSS-induced colitis.173 Given this data, selective treatment 
of ST2+ Tregs with IL-33 could provide therapeutic benefits. 
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1.7.2: Acute graft-versus-host disease 
aGVHD is a common occurrence in patients who undergo HCT as treatment for 
both malignant and non-malignant diseases of the blood and bone marrow. The 
pathogenesis of aGVHD has been well documented and is now thought to occur 
in three steps: 1) activation of antigen presenting cells (APCs) caused by tissue 
damage from the conditioning regimen leading to the release of proinflammatory 
cytokines and danger signals, 2) allo-activation of donor T cells leading to their 
proliferation and differentiation into type 1 and type 17 T cells, and 3) tissue 
destruction by alloreactive T cells through release of cytolytic molecules leading 
to donor cell apoptosis, mainly in the mucosal tissues.174 Discovering prognostic 
and diagnostic biomarkers for GVHD has been successful with sST2 being one 
of the most validated to date.42-49 Blocking sST2 with a blocking antibody during 
the peritransplant period decreased aGVHD morbidity and mortality in both minor 
histocompatibility and humanized murine models (Figure 5). Importantly, the ST2 
blocking antibody, which inhibits the full length ST2 protein and not specifically 
sST2, maintained protective ST2-expressing T cells while also not impairing the 
graft-vs-leukemia activity,75 suggesting that addition of anti-ST2 ab or a small 
molecule inhibitor of ST2 could show efficacy in reducing GVHD-related 
morbidity and mortality in patients. Using IL-33 as a treatment seems to be time-
dependent, as injection with IL-33 during the peak inflammatory response in a 
murine model led to increased morbidity and mortality in mice due to increased 
migration and increased proinflammatory cytokine production.121 IL-33 treatment 
pre-conditioning, however, increased the number of ST2+ Tregs which persisted 
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after irradiation in a murine model. This led to decreased aGVHD severity and 
mortality. Adoptive transfer of ST2+ vs ST2- Tregs showed that aGVHD protection 
is increased by ST2+ and not ST2- Tregs.82 Given that IL-33 is pleiotropic, IL-33 
treatment for aGVHD seems to be dependent on both timing and the state of 
inflammation present.   
 
1.7.3: Other gut diseases 
IL-33/ST2 signaling has been implicated in protection from various infections 
which could impact the gut. Studies have shown that treatment of mice with 
recombinant IL-33 led to epithelial cell hyperplasia in the gut along with infiltration 
of eosinophils and mononuclear cells in the lamina propria.66,175 These effects 
are thought to be mediated by IL-13, which becomes overexpressed after IL-33 
treatment.30 Treatment of mice with IL-33 after Trichuris muris infection increased 
parasite clearance through increased Th2 cytokine response.175 Other infections 
which can impact the gut, including Toxoplasma gondii,176 Leptospira,177 and 
Pseudomonas aeruginosa,178 have shown that loss of ST2 or high sST2 levels 
led to higher morbidity and mortality with increased Th1 cytokine profiles. Recent 
studies have shown that gut epithelial barrier dysfunction and immune activation 
independently predict mortality during treated HIV infection.179 A later study 
showed that patients during the early stage of HIV infection, defined as being 
within 180 days of the date of infection, had higher levels of sST2 in their plasma 
and was highly correlated with CD8 T cell count and levels of gut mucosal 
damage, but not with viral load or CD4 T cell count.96  
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sST2 increase has also been implicated during small bowel transplant rejection.50 
Patients who had rejection of small bowel transplants had higher serum levels of 
sST2 during rejection compared to that during rejection-free time points, and that 
rejection increased allograft ST2 expression. Increase in sST2 in the allograft 
was predicted by Pathway and Network Analysis to be caused by TNF-α and IL-
1β signaling.50 However, this data does not implicate sST2 as a mediator of 
disease but rather a biomarker of occurring transplant rejection. 
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Figure 5. Pathogenesis of aGVHD 
The gut and other issues are damaged during irradiation or chemotherapy, 
leading to the release of various DAMPs, PAMPs, and cytokines, including IL-33. 
These DAMPs, PAMPs, and cytokines activate both host and donor antigen 
presenting cells (APCs), which then activate the donor T cells. The APCs are 
also secreting various cytokines which promotes T cell differentiation toward a 
type 1 and type 17 response. These activated type 1 and type 17 T cells are able 
to secrete various proinflammatory cytokines, leading to apoptosis of healthy 
tissue, mainly in the gut, liver, and skin, which can be exacerbated by free IL-33. 
Furthermore, sST2 is produced by both type 1 and type 17 T cells, and while this 
may sequester free IL-33 from the type 1 and type 17 T cells, sST2 can also 
prevent the potential beneficial effects from IL-33/ST2 signaling in Th2 cells, 
Tregs, and ILC2s. 
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1.8: Research Goals 
Acute graft-versus-host disease (aGVHD) hinders the efficacy of allogeneic 
hematopoietic cell transplantation (HCT). The transfer of donor T cells in the graft 
and their recognition of recipient antigen and recipient major histocompatibility 
complex are the main drivers of aGVHD. Until recently, determining risk of 
aGVHD for patients undergoing HCT has been difficult until it was found that 
plasma soluble serum stimulation-2 (sST2) predicted aGVHD-related mortality in 
HCT patients.42 Excess sST2 sequesters IL-33, shown to increase sST2 
producing T cells (Th1/Th17) and decrease membrane ST2 (ST2) expressing 
cells (Th2/Tregs) at onset of aGVHD. Blockade of excess ST2 inverted these 
phenotypes.75  
 
Myeloid differentiation primary response 88 (MyD88) is an adapter protein vital 
for both IL-1 superfamily receptor signaling and most toll-like receptor (TLR) 
signaling. ST2, as a member of the IL-1 superfamily, signals through MyD88. 
Loss of MyD88 in CD4 conventional T cells (Tcons) has been shown to decrease 
ovalbumin or 2W peptide-stimulated Th1/Th17 cells via the IL-1 receptor (IL-1R). 
Regulatory T cells (Tregs) have been shown to keep their suppressive 
capabilities when MyD88 is lost.180 Intrinsic MyD88 signaling in T cells is also 
important for optimal T cell response to some viral infections.110,181,182 
 
MyD88 signaling during aGVHD has been studied in the context of both donor 
and host dendritic cells with mixed results.100,154 The role of MyD88 signaling in 
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the donor T cells is not understood. Given the importance of MyD88 for optimal T 
cell response, we used two mouse models of aGVHD to dissect the role of 
MyD88 in donor T cells after HCT. We hypothesized that absence of MyD88 
signaling would protect against aGVHD through IL-1R, ST2, or both.  
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CHAPTER 2: MATERIALS AND METHODS 
 
Mice 
Boy/J (C57BL/6.Ptprca, H-2b, CD45.1) and C57BL/6 (H-2b, CD45.2) mice were 
purchased from the In Vivo Therapeutics Core at the Indiana University School of 
Medicine. BALB/c (H-2d, CD45.2), C3H.SW (H-2b, CD45.2), and B6.B10ScN-
Tlr4lps-del/JthJ (TLR4-/-) mice were purchased from Jackson Laboratory. MyD88-/- 
mice provided by Dr. Steve Kunkel (University of Michigan),183 ST2-/- mice 
provided by Dr. Andrew McKenzie (University of Cambridge),184 and IL-1R-/- mice 
provided by Dr. Travis Jerde (Indiana University Purdue University of 
Indianapolis)185 were backcrossed on C57BL/6 background for at least 10 
generations. The Institutional Animal Care and Use Committee approved all 
animal protocols.  
 
CD4 T cell differentiation 
Naïve CD4+ CD62L+ T cells were purified from spleens of WT or MyD88-/- mice 
using the murine CD4+CD62L+ T Cell Isolation Kit (Miltenyi Biotec). Isolated 
naïve CD4 T cells cultured in RPMI 1640 supplemented with 10% (vol/vol) FBS 
(Hyclone), 1mM glutamine (ThermoFisher Scientific), 100 μg/mL Streptomycin 
(ThermoFisher Scientific), 100 U/mL Penicillin (ThermoFisher Scientific), 1 mM 
sodium pyruvate (ThermoFisher Scientific), 10 mM HEPES (ThermoFisher 
Scientific), and 50 μM 2-Mercaptoethanol (ThermoFisher Scientific) were 
stimulated with plate-bound αCD3 (2 μg/ml – 2C11) and soluble αCD28 (5 μg/ml 
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– 37.51) under Th0 (no additional cytokines), Th1 (20 ng/ml IL-12, 2 ng/ml IL-2), 
Th2 (20 ng/ml IL-4), or Th17 (4 ng/mL TGF-β, 20 ng/ml IL-6, 20 ng/ml IL-1β) 
conditions. On day 3 cells were expanded with media alone, except for cells 
under Th17 conditions, which received half the original cytokine cocktail along 
with media. On day 5 cells were harvested for analysis. 
 
aGVHD induction and assessment 
In the major MHC-mismatched model (B6  BALB/c), BALB/c recipient mice 
received 900 cGy of total body irradiation (137Cs as source) at day −1. In the 
miHA-mismatched aGVHD model (B6  C3H.SW), C3H.SW recipient mice 
received 1100 cGy of total body irradiation at day −1. Then, recipient mice were 
injected intravenously with WT B6 T cell–depleted (TCD) BM cells (5 × 106) plus 
WT, MyD88-/-, IL-1R-/-, TLR4-/-, or ST2-/- splenic total T cells (1 × 106 for BALB/c 
and 2 × 106 for C3H.SW, unless indicated otherwise) from either syngeneic or 
allogeneic donors at day 0. T cells from donor mice were enriched using the 
murine Pan T Cell Isolation Kit (Miltenyi Biotec), and TCD BM was prepared with 
CD90.2 Microbeads (Miltenyi Biotec). For some experiments, donor T cells were 
first labeled with CFSE before injection. In adoptive transfer models, wild-type, 
MyD88-/- and ST2-/- B6  donor Tcons or Tregs were purified first using the murine 
Pan T Cell Isolation Kit followed by the murine CD4+ CD25+ Regulatory T Cell 
Isolation Kit (Miltenyi Biotec). Purities of Tcons, defined as CD3+CD25-Foxp3- 
cells, and Tregs, defined as CD3+CD4+CD25+Foxp3+ cells, were >98% and 
>92%, respectively. For the MyD88 small molecule inhibitor experiment, the 
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ST2825 compound (MedChem Express) was first reconstituted in 100% DMSO, 
followed by dilution to a working amount (5 mg/kg/200uL in 0.1% DMSO in PBS). 
ST2825 was administered intraperitoneally twice daily from day (-1) to day 9 
post-HCT. The mice were housed in sterilized microisolator cages and 
maintained on acidified water (pH <3) for 3 weeks. Survival was monitored daily 
and clinical aGVHD scores were assessed weekly. 
 
ELISA 
We measured concentrations of murine plasma IFN-γ using DuoSet Kit and sST2 
using Quantikine Kit (R&D Systems) according to manufacturer’s protocols. 
 
Isolation and sorting of intestinal CD4 T cells  
We prepared single-cell suspensions of mononuclear cells from intestines as 
previously described.75 Isolated intestines were flushed with cold PBS to remove 
mucus and feces. The intestines were cut into <0.5 cm fragments and digested in 
10 mL of DMEM containing 4% bovine serum albumin (Sigma), 2 mg/mL 
collagenase type B (Roche), and 10 μg/mL DNase I (Roche) at 37°C with 
shaking (250rpm) for 90 minutes. The digested mixture was diluted with 30 mL 
DMEM, filtered through a 100 μm strainer, and centrifuged for 10 minutes at 
850g. The cells were resuspended in 5 mL of 80% Percoll (GE Healthcare) and 
overlaid with 8 mL of 42% Percoll. The cells were spun at 4°C for 20 minutes at 
800g without braking. The interface, which contains the live mononuclear cells 
was collected and washed twice with PBS. Live CD4+ T cells (Fixed Viability Dye-
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CD90.2+CD4+; all from eBioscience) were stained with fluorescent antibodies and 
sorted on the BD FACSAria (BD Biosciences). 
 
Flow cytometry analysis  
All antibodies and reagents for flow cytometry were purchased from eBioscience, 
unless stated otherwise. Single cell suspensions were preincubated with purified 
anti-mouse CD16/CD32 mAb for 10 to 20 min at 4°C to prevent nonspecific 
binding of antibodies. The cells were subsequently incubated for 30 min at 4°C 
with antibodies for surface staining. Fixable viability dye (FVD) was used to 
distinguish live cells from dead cells. The Foxp3/Transcription Factor Staining 
Buffer Set and the Fixation and Permeabilization Kit were used for intracellular 
transcription factor and cytokine staining. For cytokine staining, cells were 
restimulated with phorbol myristate acetate (PMA, 50 ng/ml) and ionomycin (1 
μg/ml; Sigma-Aldrich) for 4 to 6 hours, with the addition of brefeldin A during the 
last 2 hours of stimulation, before any staining. Staining antibodies against 
mouse antigens included: anti-CD45.1, anti-CD45.2, anti-CD90.2, anti-CD4, anti-
CD8, anti-Foxp3, anti-IL-4, anti-IFNγ, anti-IL-17, anti-GM-CSF, annexin V, anti-
CCR5, and anti-α4β7. Cells were analyzed using BD LSRFortessa (BD 
Biosciences) and results were analyzed using FlowJo (Tree Star). 
 
Nanostring analysis 
Sorted intestinal CD4 T cells were prepared and analyzed as previously 
described.75 Sorted intestinal CD4 T cells from either recipients of WT or MyD88-
54 
/- allogeneic donor T cells were directly lysed in RLT buffer (Qiagen) on ice. Cell 
concentration for each sample was 2 × 103 cells/μL. Preparation of samples for 
analysis was then performed according to the Nanostring Technologies protocol 
for gene expression. Plates were run on the nCounter SPRINT ProfilerAnalysis 
System and the data analysis using nSolver 3.0. The nCounter Mouse 
Immunology Kit, which includes 561 immunology-related mouse genes, was 
used in the study. 
 
Quantitative PCR 
Total RNA from sorted intestinal T cells (Fixed Viability Dye-CD3+, all from 
eBioscience), were isolated using the RNeasy Plus Mini Kit (Qiagen). 
Complementary DNA (cDNA) was prepared with the SuperScript VILO cDNA 
Synthesis Kit (Invitrogen). Using an ABI Prism7500HT (Applied Biosystems), 
quantitative real-time PCR was performed with the SYBR Green PCR mix. 
Thermocycler conditions included 2-min incubation at 50°C, then at 95°C for 10 
min; this was followed by a two-step PCR program: 95°C for 5 s and 60°C for 60 
s for 40 cycles. β-Actin was used as an internal control to normalize for 
differences in the amount of total cDNA in each sample. The primer sequences 
were as follows: actin forward, 5′-CTCTGGCTCCTAGCACCATGAAGA-3′; actin 
reverse, 5′- GTAAAACGCAGCTCAGTAACAGTCCG-3′; ST2 forward, 5′-
AAGGCACACCATAAGGCTGA-3′; ST2 reverse, 5′-
TCGTAGAGCTTGCCATCGTT-3′; sST2 forward, 5′-
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TCGAAATGAAAGTTCCAGCA-3′; sST2 reverse, 5′-
TGTGTGAGGGACACTCCTTAC-3′. 
 
Western Blot 
CD4 and CD8 T cells were isolated from WT B6 spleens using CD4 microbeads 
and CD8 microbeads (both from Miltenyi Biotec), respectively, following 
manufacturer’s protocols. Purities of CD4 and CD8 T cells after selection were 
>95%. Sorted cells were lysed in RIPA buffer (Pierce Biotechnology) with Pierce 
Phosphatase Inhibitor MiniTablets (Pierce Biotechnology) and Protease Inhibitor 
Cocktail Tablets (Roche). Samples were boiled, electrophoretically separated, 
and transferred on Immobilon-FL polyvinylidene difluoride membranes (Millipore). 
The blots were blocked with Odyssey Blocking Buffer (LI-COR) for 1 hour at 
room temperature and incubated with specific primary antibodies: rabbit MyD88 
mAb (D80F5, Cell Signaling Technology) and anti–β-actin mAb (LI-COR), both at 
4°C overnight. IRDye 800CW goat anti-rabbit (LI-COR) and IRDye 680RD goat 
anti-mouse IgG polyclonal antibodies (LI-COR) were used as secondary 
detection antibodies for MyD88 and β-actin, respectively. Fluorescence from 
blots was then developed with the Odyssey CLx Imaging System (LI-COR) 
according to the manufacturer’s instructions. 
 
Statistical Analysis 
Log-rank test was used for survival analysis. Differences between two groups 
were compared using 2-tailed unpaired t tests. Bonferroni correction was used 
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when comparing multiple groups. All statistical analyses were performed using 
GraphPad Prism, version 7.02. Data in graphs represent mean ± standard error 
of the mean (SEM). P values less than 0.05 were considered significant. 
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CHAPTER 3: RESULTS 
 
3.1 MyD88-/- T cells reduce aGVHD morbidity and mortality in multiple 
murine models 
First, we tested whether loss of MyD88 affected normal splenic T cells in naïve 
mice. We found no difference in splenic T cell numbers; CD4/CD8 frequency; or 
naïve, memory, and effector frequencies (Figure 6a). Ability to polarize toward 
Th1, Th2, or Th17 cells in vitro was also not affected by the absence of MyD88 
as shown by IFN-γ, IL-4, or IL-17 production, respectively (Figure 6b). To explore 
the role of MyD88 signaling in the donor T cells in vivo following HCT, we used 
two clinically relevant murine HCT models: C57BL/6  BALB/c and C57BL/6  
C3H.SW. In both models splenic T cells were isolated and bone marrow cells 
were depleted of T cells. In the MHC-major mismatch model C57BL/6  BALB/c, 
mice receiving WT T cells quickly developed and succumbed to severe aGVHD 
(median survival time: 14 days). However, mice receiving MyD88-/- T cells had 
decreased aGVHD scores and mortality (median survival time: >30 days) 
compared to mice receiving WT T cells (Table 1; Figure 7a,b). IFNγ production 
by donor T cells in the intestine at day 10 post-HCT was lower in the MyD88-/- T 
cells than the WT T cells (Figure 7c). Systemically, plasma levels of IFNγ and 
sST2 were lower in recipients of MyD88-/- T cells than those receiving WT T cells 
(Figure 7d). Using the miHA model, C57BL/6  C3H.SW, we observed a similar 
decrease in aGVHD mortality (median survival time: WT - 43 days; MyD88-/- - 
>60 days; Figure 8a,b). Similarly to that seen in the major mismatch model, both 
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IFNγ production by MyD88-/- donor T cells was lower compared to that from WT T 
cells and plasma levels of IFNγ and sST2 were lower in recipients of MyD88-/- T 
cells compared to those receiving WT T cells (Figure 8c,d). These results show 
that signaling through MyD88 in the donor T cells is critical in the pathogenesis of 
aGVHD.  
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Figure 6. Comparison of splenic T cells from naïve WT or MyD88-/- mice 
(A) Cell number and frequencies of total, CD4, or CD8 T cells (left); naïve, 
memory, and effector CD4 or CD8 populations (right) harvested from spleen of 
WT or MyD88-/- mice (mean ± SEM; n=3). (B) Naïve CD4 T cells were stimulated 
with plate-bound αCD3 (2 μg/ml) and soluble αCD28 (5 μg/ml) under Th0 (no 
additional cytokines), Th1 (20 ng/ml IL-12, 2 ng/ml IL-2), Th2 (20 ng/ml IL-4), or 
Th17 (4 ng/mL TGF-β, 20 ng/ml IL-6, 20 ng/ml IL-1β) conditions for 5 days. 
Graphs show frequency of IFN-γ (left), IL-4 (middle), and IL-17 (right) expression 
(mean ± SEM; n=3).   
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Table 1. aGVHD Clinical Score Assessment in Transplanted Mice 
  
Criteria Grade 0 Grade 0.5 Grade 1.0 Grade 1.5 Grade 2.0 
Weight 
loss 
<10% N/A 10-24.9% N/A ≥25% 
Posture No hunch Slight 
hunch, 
straightens 
when walks 
Animal 
stays 
hunched 
when walks 
Animal 
does not 
straighten 
out 
Animal 
tends to 
stand on 
rear toes. 
Mobility Very 
mobile,  
hard to 
catch 
Slower than 
naïve, 
easier to 
catch 
Not moving, 
but will 
move when 
poked 
Not moving, 
moves 
slightly 
when poked 
Not 
moving, 
won’t 
move if 
poked 
Skin No redness, 
abrasions, 
lesions or 
scaling 
present 
Redness in 
one area 
only 
Abrasions 
in 1 area, or 
mild 
abrasions in 
2 areas 
Bad 
abrasions in 
2 areas 
Extremely 
bad 
abrasion, 
cracking 
skin, dried 
blood etc. 
Fur No fur 
pathology 
Ridging on 
the side of 
belly or 
nape of 
neck 
Ridging 
across or 
the side of 
belly + neck 
Unkempt 
matted and   
ruffled fur 
Badly 
matted fur 
on belly, 
and on top 
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Figure 7. aGVHD assessment using WT or MyD88-/- donor T cells in a major 
MHC mismatch model 
(A) Schematic for allo-transplantation using WT or MyD88-/- donor T cells and WT 
BM in the B6  BALB/c major MHC mismatch model. (B) Lethally irradiated 
BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells and 1 x 106 donor T 
cells from WT or MyD88-/- B6 mice for allogeneic transplant or WT BALB/c TCD 
BM and donor T cells from WT BALB/c mice for syngeneic transplant (Syn). 
aGVHD score (left) and survival (right); BALB/c  BALB/c (n=5), B6 WT (n=15), 
or B6 MyD88-/- total T cells (n=15) groups. (C) Representative flow plots (left) and 
column scatter plot (right) showing frequency of IFN-γ positive total T cells in the 
intestine of recipient BALB/c mice transplanted with WT or MyD88-/- T cells at day 
10 post-HCT. (D) IFN-γ (left) and sST2 (right) protein levels in the plasma of 
recipient mice transplanted with WT or MyD88-/- T cells collected at days 5 and 
10 post-HCT. *p < 0.05, **p < 0.01, ***p < 0.001  
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Figure 8. aGVHD assessment using WT or MyD88-/- donor T cells in a minor 
MHC mismatch model 
(A) Schematic for allo-transplantation using WT or MyD88-/- donor T cells and WT 
BM in the B6  C3H.SW minor MHC mismatch model. (B) Lethally irradiated 
C3H.SW mice (1100 cGy) were given 5 x 106 TCD-BM cells and 2 x 106 donor T 
cells from WT or MyD88-/- B6 mice for allogeneic transplant or WT C3H.SW TCD-
BM and donor T cells from WT C3H.SW mice for syngeneic transplant. aGVHD 
score (left) and survival (right); C3H.SW  C3H.SW (n=5), B6 WT (n=6), or B6 
MyD88-/- total T cells (n=6). (C) Representative flow plots (left) and column 
scatter plot (right) showing frequency of IFN-γ positive total T cells in the intestine 
of recipient C3H.SW mice transplanted with WT or MyD88-/- T cells at day 10 
post-HCT. (D) IFN-γ (left) and sST2 (right) protein levels in the plasma of 
recipient mice transplanted with WT or MyD88-/- T cells collected at days 5 and 
10 post-HCT. *p < 0.05, **p < 0.01  
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3.2 MyD88-/- donor T cells do not have defects in their proliferation, 
apoptosis, migration, or Th2 and Treg frequencies following HCT 
To determine if the donor MyD88-/- T cells had a defect in proliferation, apoptosis, 
or migration following HCT, we stained the CD45.1 WT T cells and CD45.2 
MyD88-/- T cells with carboxyfluorescein succinimidyl ester (CFSE) right before 
transplantation and injected them into lethally irradiated recipients at a 1:1 ratio. 
At day 3 post-HCT, we did not observe a difference in proliferation between 
groups (Figure 9a). We then isolated cells from the spleen, liver, mesenteric 
lymph nodes, and intestine at day 10 post-HCT to test for differences in 
apoptosis, measured using annexin V. We found no differences between groups 
in apoptosis of T cells in the intestine at days 3, 5, and 10 post-HCT (Figure 9b). 
We also did not observe any differences in the expression of the chemokine 
receptor CCR5 or the integrin α4β7 in the intestine at day 10 post-HCT (Figure 
9c), both of which have been implicated in the migration of T cells to the 
intestine.186,187 Th2188 and Treg189 cells have been shown to be protective against 
aGVHD; however, we found no difference in IL-4 production (Figure 10a) or 
Foxp3 expression (Figure 10b) in the donor T cells from the intestine at 10 days 
post-HCT. Together, these data show that following HCT the expansion, 
apoptosis, migration, or Th2 and Treg differentiation of MyD88-/- donor T cells is 
different from WT donor T cells. 
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Figure 9. Proliferation, apoptosis, and migration of transplanted WT vs 
MyD88-/- T cells 
Lethally irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells and 
1 x 106 CFSE labeled donor T cells from WT CD45.1 or MyD88-/- CD45.2 B6 
mice. (A) Proliferation of CFSE labeled T cells from WT CD45.1 or MyD88-/- 
CD45.2 donors harvested from the intestine at day 3 post-HCT. (B) Annexin V 
staining of T cells from WT CD45.1 or MyD88-/- CD45.2 donors harvested from 
the intestine at days 3, 5, and 10 post-HCT (mean ± SEM, n=2).  (C) CCR5 and 
α4β7 expression on T cells from WT CD45.1 or MyD88-/- CD45.2 donors 
harvested from the intestine at day 5 post-HCT (mean ± SEM, n=2).  
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Figure 10. Th2 and Treg frequencies in the intestine of mice receiving WT 
or MyD88-/- donor T cells 
Lethally irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells and 
1 x 106 donor T cells from WT or MyD88-/- B6 mice for allogeneic transplant. T 
cells were harvested from the intestine at day 10 post-HCT and stained for 
expression of (A) CD4 and Foxp3 or (B) CD4 and IL-4 (mean ± SEM, n=3). 
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3.3 Loss of IL-1R or TLR4, both upstream of MyD88, on T cells does not 
alleviate aGVHD 
To elucidate the mechanism as to why MyD88-/- donor T cells induce less severe 
aGVHD, we targeted upstream receptors of MyD88. The upstream receptors for 
MyD88 include the IL-1 receptor superfamily and the toll-like receptor (TLR) 
family, with the exception of TLR3.190,191 One group has shown that MyD88-/- 
CD4 T cells produce less IFN-γ and proliferate less than WT CD4 T cells after 
immunization and this was due to defective IL-1R signaling.180 Another group 
found that, in an aGVHD model, recipients of IL-1R-/- T cells survived longer than 
recipients of WT T cells.192 Thus, we next asked whether the phenotype 
observed using MyD88-/- donor T cells is mediated through IL-1R. In our models, 
we found no difference between groups in clinical score or survival from mice 
receiving WT or IL-1R-/- donor T cells in either the MHC-major mismatch model 
(median survival time: WT - 14 days; IL-1R-/- - 28 days; Figure 11a) or the miHA 
model (median survival time: WT - 43 days; IL-1R-/- - 39 days; Figure 11b). 
Another group showed that recipients of TLR4-/- BM and T cells together reduced 
aGVHD severity compared to WT recipients through defective donor APC 
response, but did not test whether TLR4-/- T cell response compared to WT was 
also affected.193 So, we asked whether loss of TLR4 on the donor T cells could 
affect aGVHD severity and mortality. Recipients of TLR4-/- donor T cells both 
models did not reduce aGVHD severity and mortality (Major model median 
survival time: WT - 10 days; TLR4-/- - 9 days; Figure 12a; Minor model median 
survival time: WT - 18 days; TLR4-/- - 33 days; Figure 12b). These data show that 
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IL-1R and TLR4 signaling in donor T cells do not play major roles for aGVHD 
induction.  
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Figure 11. IL-1R-/- donor T cells in aGVHD 
(A) Lethally irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells 
and 1 x 106 donor T cells from WT or IL-1R-/- B6 mice for allogeneic transplant or 
WT BALB/c TCD-BM and donor T cells from WT BALB/c mice for syngeneic 
transplant. aGVHD score (left) and survival (right); BALB/c  BALB/c (n=5), B6 
WT (n=15), or B6 IL-1R-/- total T cells (n=8). (B) Lethally irradiated C3H.SW mice 
(1100 cGy) were given 5 x 106 TCD-BM cells and 2 x 106 donor T cells from WT 
or IL-1R-/- B6 mice for allogeneic transplant or WT C3H.SW TCD-BM and donor 
T cells from WT C3H.SW mice for syngeneic transplant. aGVHD score (left) and 
survival (right); C3H.SW  C3H.SW (n=5), B6 WT (n=6), or B6 IL-1R-/- total T 
cells (n=6).  
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Figure 12. TLR4-/- donor T cells in aGVHD 
(A) Lethally irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells 
and 1 x 106 donor T cells from WT or TLR4-/- B6 mice for allogeneic transplant. 
aGVHD score (left) and survival (right); B6 WT (n=8) or B6 TLR4-/- total T cells 
(n=8). (B) Lethally irradiated C3H.SW mice (1100 cGy) were given 5 x 106 TCD-
BM cells and 2 x 106 donor T cells from WT or TLR4-/- B6 mice for allogeneic 
transplant. aGVHD score (left) and survival (right); B6 WT (n=8) or B6 TLR4-/- 
total T cells (n=8).  
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3.4 Transplantation of donor MyD88-/- CD4 T cells, but not CD8 T cells, 
reduces aGVHD severity independent of intrinsic MyD88 signaling 
MyD88 signaling in T cells has been characterized in both the CD4 and the CD8 
compartments.180,181,194,195 We found higher expression of MyD88 in CD4 than 
CD8 T cells (Figure 13a). The importance of MyD88 signaling in donor CD4 and 
CD8 cells in the context of aGVHD has not been studied. To determine if MyD88 
in CD4 T cells, CD8 T cells, or both is important for aGVHD development, we 
isolated WT CD4, WT CD8, MyD88-/- CD4, and MyD88-/- CD8 T cells from naïve 
mice. Transplanting MyD88-/- CD4 T cells with WT CD8 T cells increased the 
survival of the recipient mice compared to transplanting WT CD4 T cells with 
MyD88-/- CD8 T cells (median survival time: MyD88-/- CD4 - >60 days; MyD88-/- 
CD8 - 36 days; Figure 13b,c), the former showing a similar phenotype to total WT 
T cell recipients. These data show that MyD88 signaling in CD4 T cells, but not 
CD8 T cells, is needed for optimal aGVHD induction. GM-CSF expression by T 
cells has been implicated in experimental autoimmune encephalomyelitis (EAE), 
an animal model of multiple sclerosis, through a STAT5 dependent 
mechanism.196,197 We found that production of GM-CSF in the intestine 10 days 
post-HCT is decreased when transplanting MyD88-/- CD4 cells compared to WT 
CD4 cells (Figure 13d). 
 
The CD4 T cell compartment consists of both pro-inflammatory Tcons and anti-
inflammatory Tregs. MyD88+/+ Tregs prolong allograft survival in both organ 
transplantation and chronic GVHD (cGVHD) through a cell-intrinsic 
78 
mechanism.198 We next explored the cell-intrinsic role of MyD88-/- Tregs in 
aGVHD. We did not observe a difference in survival using using WT Tcons with 
WT or MyD88-/- Tregs (median survival time: WT Tregs - 26 days; MyD88-/- Tregs 
- 24 days; Figure 14a). Intrinsic MyD88 signaling in CD4 T cells has also been 
implicated in mounting a proper antiviral response.182 After transplanting Treg-
depleted WT or MyD88-/- Tcons, we did not observe a difference in aGVHD 
severity or mortality (median survival time: WT Tcon - 10 days; MyD88-/- Tcon - 
10 days; Figure 14b). These data indicate that intrinsic MyD88 signaling in donor 
T cells does not impact aGVHD. 
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Figure 13. CD4 vs CD8 MyD88-/- donor T cells in aGVHD 
(A) Representative Western blot of MyD88 from freshly isolated CD4 or CD8 T 
cells from a WT B6 spleen. (B) Schematic for allo-transplantation using WT or 
MyD88-/- donor CD4 and CD8 cells and WT BM in the B6  C3H.SW minor MHC 
mismatch model. (C) Lethally irradiated C3H.SW mice (1100 cGy) were given 5 x 
106 TCD-BM cells and a mixture of 2 x 106 WT CD4 + MyD88-/- CD8 or MyD88-/- 
CD4 + WT CD8 donor T cells from B6 mice for allogeneic transplant or WT 
C3H.SW TCD-BM and donor T cells from WT C3H.SW mice for syngeneic 
transplant. aGVHD score (left) and survival (right); C3H.SW  C3H.SW (n=6), 
B6 WT CD4 + MyD88-/- CD8 T cells (n=6), or B6 MyD88-/- CD4 + WT CD8 T cells 
(n=6). (D) T cells were harvested from the intestine at day 10 post-HCT and 
stained for live GM-CSF producing CD4 T cells.   
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Figure 14. Intrinsic MyD88 signaling in Tcons and Tregs during aGVHD 
(A) Lethally irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells 
and 1 x 106 donor Tcons without Tregs from WT or MyD88-/- B6 mice for 
allogeneic transplant or WT BALB/c TCD-BM and donor T cells from WT BALB/c 
mice for syngeneic transplant. aGVHD score (left) and survival (right); BALB/c  
BALB/c (n=5), B6 WT Tcons (n=7), or B6 MyD88-/- Tcons (n=7). (B) Lethally 
irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells and a 5:1 
mixture of WT Tcon + WT or MyD88-/- Tregs totaling 1 x 106 donor T cells from 
B6 mice for allogeneic transplant or WT BALB/c TCD-BM and donor T cells from 
WT BALB/c mice for syngeneic transplant. aGVHD score (left) and survival 
(right); BALB/c  BALB/c (n=5), B6 WT Tcons and B6 WT Tregs (n=7), or B6 
WT Tcons and B6 MyD88-/- Tregs (n=7).   
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3.5 MyD88-/- Tcons require the presence of Tregs for full alleviation of 
aGVHD 
Immunization of CD4 specific MyD88-/- mice has been shown to result in 
decreased IFN-γ production by CD4 T cells compared to WT CD4 T cells; 
however, IFN-γ levels after immunization were the same between WT and 
MyD88-/- CD4 T cells when Tregs were absent.180 As the survival of mice 
receiving WT of MyD88-/- Tcons without Tregs was not different, we tested 
whether the presence of Tregs is necessary for protection when using MyD88-/- 
donor Tcons. Indeed, use of MyD88-/- Tcons with WT or MyD88-/- Tregs, led to 
aGVHD amelioration (Figure 15a). These data show that loss of extrinsic MyD88 
signaling in Tcons in the presence of Tregs reduces aGVHD severity and 
mortality. Transcriptome analysis from day 10 post-HCT comparing WT or 
MyD88-/- CD4 Tcons recovered from the intestines showed that MyD88-/- CD4 
Tcons express lower levels of genes involved in the inflammatory response, 
including Il1rl1 (gene of ST2), Ifng, Csf2 (gene of GM-CSF), Stat5, and Jak2 
(Figure 15b). MyD88-/- T cells recovered from the intestine at day 10 post-HCT 
expressed less sST2 and more ST2 compared to WT T cells (Figure 15c, left). 
Systemic levels of IFN-γ and sST2 in recipients of MyD88-/- T cells were also 
decreased at days 5 and 10 post-HCT compared to recipients of WT T cells 
(Figure 15c, right). 
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Figure 15. MyD88-/- Tcons versus MyD88-/- Tregs during aGVHD 
(A) Lethally irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells 
and a 10:1 mixture of WT or MyD88-/- Tcon + WT or MyD88-/- Tregs totaling 1 x 
106 donor T cells from B6 mice for allogeneic transplant. aGVHD score (left) and 
survival (right); WT or MyD88-/- Tcons + either WT or MyD88-/- Tregs (all groups 
n=6). (B) Transcriptome analysis comparing intestinal WT and MyD88-/- CD4 T 
cells harvested 10 days post-HCT (n=2 per group). (C,D) Lethally irradiated 
BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells and 1 x 106 donor T 
cells from WT or MyD88-/- B6 mice for allogeneic transplant. (C) Relative 
expression of sST2 and mST2 from WT or MyD88-/- T cells harvested from the 
intestine 10 days post-HCT (mean ± SEM, n=4). (D) Kinetics of plasma levels of 
sST2 and IFN-γ in BALB/c mice collected at days 5 and 10 post-HCT (mean ± 
SEM, n=3). *p < 0.05, **p < 0.01, ***p < 0.001  
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3.6 ST2/MyD88 signaling in Tcons is necessary for aGVHD development 
We hypothesized that this protective phenotype observed when transplanting 
MyD88-/- Tcons in the presence of Tregs was mediated by a lack of ST2 signaling 
on donor Tcons. Recipients of ST2-/- Tcons with either WT or ST2-/- Tregs had 
lower aGVHD mortality, mirroring the phenotype seen using MyD88-/- Tcons 
(Figure 16A). Clinical score and survival of recipients of total MyD88-/- and ST2-/- 
donor T cells phenocopy each other (Figure 16B). These data confirm that 
alloreactive T cells in the intestines produce sST2, as we previously suggested,75 
and that targeting ST2/MyD88 signaling in Tcons could alleviate aGVHD while 
sparing Treg function. 
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Figure 16. ST2 vs MyD88 signaling during aGVHD 
(A) Lethally irradiated C3H.SW mice (1100 cGy) were given 5 x 106 TCD-BM 
cells and a 10:1 mixture of WT or ST2-/- Tcon + WT or ST2-/- Tregs totaling 2 x 
106 donor T cells from WT or ST2-/- B6 mice for allogeneic transplant. aGVHD 
score (left) and survival (right) (all groups n=6). (B) Lethally irradiated BALB/c 
mice (900 cGy) were given 5 x 106 TCD-BM cells and 1 x 106 donor T cells from 
WT, MyD88-/-, or ST2-/- B6 mice for allogeneic transplant. aGVHD score (left) and 
survival (right) (all groups n=6). *p < 0.05, **p < 0.01  
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3.7 MyD88 signaling blockade using a small molecule inhibitor 
We tested blocking MyD88 signaling in vivo using the small molecule inhibitor 
ST2825, which prevents the homodimerization of MyD88 at their TIR domain, 
preventing downstream signaling.199 MyD88 signaling blockade using ST2825 
injected intraperitoneally twice a day (5 mg/kg per injection) from day (-1) to day 
9 post-HCT did not affect aGVHD severity or mortality in the B6  BALB/c model 
(Figure 17). 
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Figure 17. Blockade of MyD88 signaling using ST2825 during aGVHD 
Lethally irradiated BALB/c mice (900 cGy) were given 5 x 106 TCD-BM cells from 
WT B6 mice and 1 x 106 donor total T cells from B6 WT or MyD88-/- mice for 
allogeneic transplant. Recipient mice receiving WT T cells were injected with 
either vehicle control or ST2825 (5 mg/kg) intraperitoneally twice a day for 10 
days beginning at day (-1). Recipient mice receiving MyD88-/- T cells were 
injected with vehicle control intraperitoneally twice a day for 10 days beginning at 
day (-1). aGVHD score (left) and survival (right); WT (n=5), MyD88-/- (n=5), or 
ST2825 (n=5). p > 0.05 between WT and ST2825  
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CHAPTER 4: DISCUSSION 
 
4.1 Summary of Results 
Genetic knockouts of ST2 on T cells and blocking of ST2 using a neutralizing 
antibody has been shown to ameliorate aGVHD.75 However, these experiments 
used knockout mice that lacked both membrane ST2 and sST2 and the 
neutralizing antibody also was not specific for either form of ST2. These 
experiments also did not show mechanistically how loss of ST2 reduces aGVHD. 
Here, we show that ST2/MyD88 signaling in donor T cells during HCT is 
important for aGVHD progression through prevention of Treg-mediated 
suppression of effector T cells. We used two murine models of aGVHD to show 
how loss of MyD88 in the donor T cells decreases aGVHD severity and mortality. 
Unlike in other models, which has suggested a role of IL-1 receptor/MyD88180,192 
and TLR4/MyD88193 signaling in promoting an optimal T cell response in vivo, we 
did not observe a difference in the development of aGVHD using donor T cells 
from IL-1 receptor or TLR4 knockout mice. Neither loss of MyD88 in Tcons 
adoptively transferred alone without Tregs nor loss of MyD88 in adoptively 
transferred Tregs with WT Tcons affected aGVHD progression. Amelioration of 
aGVHD was only observed when transplanting MyD88-/- Tcons in the presence of 
Tregs, suggesting that loss of MyD88 in Tcons sensitizes them to Treg-mediated 
suppression. Strikingly, results using ST2-/- donor Tcons mimic the MyD88-/- 
donor Tcon phenotype, suggesting that loss of MyD88 in donor Tcons 
ameliorates murine aGVHD in an ST2-dependent manner. 
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4.2 MyD88 in T cells 
Previous studies using MyD88-/- T cells have shown that MyD88 is necessary for 
optimal CD4 and CD8 T cell responses in vivo.180-182,200 We found no differences 
in the ability of T cells to produce IFN-γ, IL-4, or IL-17 under Th1, Th2, or Th17 
polarizing conditions, respectively, when using αCD3/αCD28 polyclonal 
stimulation. However, during antigen-specific responses, T cells require MyD88 
for differentiation of Th1 and Th17 cells.180-182,194,200 In the context of aGVHD, we 
have shown that MyD88 in T cells is necessary for optimal allo-response. Loss of 
MyD88 in the donor T cells leads to decreased aGVHD severity and mortality in 
two different murine models: a major-MHC mismatch model and a minor-MHC 
mismatch model. However, our results are different from those previously 
published, in which a haploidentical aGVHD murine model, C57BL/6 (H-2b) → 
B6D2F1 (H-2b/d) was used. Using this model, no difference in aGVHD severity 
was observed when transplanting MyD88-/- T cells.201 We believe the discrepancy 
in results to be due to low number of T cells injected into the irradiated B6D2F1 
recipients compared to what is normally used in that model.202,203  Using a lower 
number of T cells during HCT can lengthen the kinetics of aGVHD development 
and reduce the severity and mortality of aGVHD. The delayed onset and reduced 
severity and mortality may not have allowed any differences in aGVHD to be 
observed.  
 
It has been shown that diminished Th1 and Th17 responses due to loss of 
MyD88 are a product of loss of IL-1R signaling on CD4 T cells.180 As well, WT T 
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cells upregulate IL-1R on their surface by day 3 post-HCT and transplanting IL-
1R-/- donor T cells alleviated aGVHD in a major-mismatch model.192 However, we 
have found that IL-1R-/- donor T cells have no significant loss of effector function, 
as aGVHD was not attenuated in our two models. Our results are more in 
accordance with what has been shown examining MyD88 signaling in T cells in 
response to viral infection. After transfer of IL-1R-/- or MyD88-/- T cells into RAG-/- 
mice and infecting with vaccinia virus, mice with IL-1R-/- CD8 T cells were able to 
respond to the infection normally while mice with MyD88-/- CD8 T cells mounted a 
reduced response.200 Similar results were found during LCMV infection in CD8 T 
cells.181 Looking at WT, MyD88-/-, and IL-1R-/- CD4 T cells in absence of CD8 T 
cells in response to LCMV infection, WT and IL-1R-/- mice developed wasting 
disease and had lower virus levels while MyD88-/- mice did not develop wasting 
disease and had higher virus levels due to failure to induce LCMV-specific CD4 T 
cell response. This response was not due to impaired APC function.182 Our 
results also are in accordance with a clinical trial that observed no difference in 
aGVHD outcomes in HCT patients when using prophylactic treatment with IL-1 
receptor antagonist, an IL-1R inhibitor.204 This discrepancy in our results along 
with the results in the literature looking at anti-viral response and a clinical trial 
with those shown others could be due to the difference in models. One used an 
immunization model, while our models and others use alloresponses and viral 
responses for stimulation, respectively. It is possible that the different use of 
antigens could impact which receptors become upregulated on T cells. IL-1R is 
upregulated on 2W:I-Ab tetramer-positive T cells but not 2W:I-Ab tetramer-
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negative T cells after antigen stimulation. The immunization model also does not 
take into account the presence of a variety of other molecules that would be 
present in a diseased state. PAMPs, DAMPs, and alarmins released during viral 
infection or during conditioning for allo-transplant but not during immunization 
could impact T cell response to IL-1 signaling. A difference in the microbiota of 
the recipient mice could also explain this difference. Recent work has shown that 
the makeup of the intestinal microbiome can affect aGVHD severity.154,205-207 The 
mice from commercial vendors which are purchased for experiments can have 
significantly different microbiotas which can impact immune response.208 
Aberrant IL-1/IL-1R signaling has been shown to alter the microbiota in mice.209 
We purchased the BALB/c mice in our experiments from The Jackson Laboratory 
while the other group purchased their BALB/c mice from Charles River, Harlan, 
or from the local stock of the animal facility at Freiburg University Medical 
Center.192 It is possible that the difference in phenotype we saw compared what 
has been published is in part due to differences in intestinal microbiota of the 
recipients. 
 
It is also possible that there is an unknown link between MyD88 and the TCR 
complex that is explaining our difference. Clearly, cross-linking CD3 with αCD3 
stimulation in the presence of αCD28 leads to no noticeable difference between 
WT and MyD88-/- T cell differentiation and cytokine production in vitro, as 
mentioned earlier. Most of the work showing a difference has used APCs to 
stimulate TCR. No work has yet been done looking at T cell co-receptors and if 
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there is any change in their expression or signaling in MyD88-/- T cells. An 
importance for MyD88 recruitment during B cell synapse formation has been 
identified, as loss of MyD88/DOCK8 signaling impairs ICAM-1 
accumulation,210,211 a known integrin at immune synapses.212 Recently, it has 
been shown that DOCK8 is important for Treg immune synapse formation and 
loss of DOCK8 selectively in Tregs lead to autoimmune disease. DOCK8-/- mice 
do not develop autoimmunity, however, suggesting that DOCK8 signaling may be 
important in optimal Tcon function as well.213 It is therefore possible that 
MyD88/DOCK8 signaling in T cells may play a similar or an unidentified role at 
the immune synapse. 
 
During conditioning pre-HCT, intestinal mucosa is injured leading to the release 
of DAMPs, PAMPs, and alarmins. Tight junctions are damaged and LPS, among 
other bacterial products, is released into the body. LPS signals through TLR4 
and MyD88. TLR4 is found on both human and murine CD4 T cells, but its 
function is not well understood. One study showed that only naïve murine T cells 
and not activated T cells express TLR4.214 However, TLR4 on human T cells was 
only detected in activated CD4 T cells.215 In a murine model of EAE, TLR4-/- T 
cells transferred into RAG1-/- followed by EAE induction did not produce 
disease.216 However, in a spontaneous model of colitis, IL-10-/-TLR4-/- T cells 
transferred into RAG1-/- mice accelerated disease progression.217 During 
aGVHD, we found that TLR4 signaling in donor T cells was not necessary. A lack 
of TLR4 expression on activated T cells could explain why we didn’t see any 
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difference when using TLR4-/- donor T cells, but we did not test for TLR4 surface 
expression post-HCT. Our data contrasts that found by others, who found that 
using TLR4-/- as donors does indeed protect against aGVHD.193 We believe this 
difference is caused by the use of TLR4-/- BM and TLR4-/- T cells together 
compared to our use of WT BM and TLR4-/- T cells. As donor dendritic cells are 
present in the BM during transplantation and as it is well documented that TLR4 
stimulation of dendritic cells triggers their maturation and cytokine expression, we 
believe that the protective phenotype observed is caused by TLR4-/- on these 
dendritic cells.  
 
MyD88 signaling has been shown to be important in both CD4 and CD8 T cell 
responses to viruses, as MyD88-/- T cells show impaired anti-viral 
clearance;181,182,200 however, its role in CD4 and CD8 T cells during aGVHD is 
not known. When transplanting WT CD4 T cells with MyD88-/- CD8 T cells, we 
observed no difference in aGVHD severity or mortality. When transplanting 
MyD88-/- CD4 T cells with WT CD8 T cells, we observed a decrease in aGVHD 
severity and an increase in survival. This is in accordance with the findings that 
MyD88-/- CD4 T cells have impaired function during coronavirus 
encephalomyelitis while MyD88-/- CD8 T cells appear normal.218 Transcriptome 
analysis using Nanostring of CD4+ T cells from the intestine 10 days post-HCT 
also showed that genes responsible for a potent type 1 response to be 
downregulated in mice receiving MyD88-/- T cells. Interestingly, GM-CSF 
production was lower in MyD88-/- CD4 T cells but not CD8 T cells. It has recently 
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been shown that loss of GM-CSF in the donor T cells attenuates aGVHD and 
that GM-CSF production in the donor T cells is mediated through basic leucine 
zipper transcription factor, ATF-like (BATF) signaling.219 Our Nanostring data 
suggests that loss of MyD88 impacted BATF expression, as BATF expression is 
much lower in MyD88-/- CD4 T cells than in WT CD4 T cells. Exploration of 
MyD88/BATF/GM-CSF regulation would help to understand how MyD88 affect 
GM-CSF production.  
 
The CD4 T cell compartment consists of both Tcons and Tregs, with Tcons 
promoting aGVHD and Tregs alleviating aGVHD. In a colitis model in which 
naïve CD4+ CD45RB+ T cells are transplanted into RAG1-/- recipients, which lack 
mature T and B cells, MyD88-/- cells were unable to induce severe colitis.220 Our 
transplantation of WT or MyD88-/- Tcons without Tregs, however, demonstrated 
no difference in aGVHD severity or mortality. The discrepancy observed could be 
due to the difference in pro-inflammatory cytokines observed between models. 
This colitis model is dependent on IL-17 production from Th17 cells, and MyD88-/- 
CD4 T cells did indeed produce less IL-17. A difference in the Th1 cytokine IFN-γ 
was not observed.220 Our aGVHD model is dependent on IFN-γ and other type 1 
cytokine production from Th1 cells, and IFN-γ was significantly lower in the 
plasma of MyD88-/- recipients. It has been shown that Treg-specific MyD88-/- cells 
have no impairment of suppressive capability compared to WT Treg.180 
Meanwhile, it has also been shown that MyD88-/- Tregs during skin 
transplantation and cGVHD are deficient in their suppressive capabilities.198 
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MyD88-/- Tregs also protect less against colitis compared to WT Tregs;220 
however, we found that transplantation with donor WT Tcons and either WT or 
MyD88-/- Tregs did not alleviate aGVHD. The difference in our data could be due 
to the kinetics of disease. In the skin transplant model, Treg frequencies were 
similar early after transplant and only started to decrease after 21 days post-skin 
transplant.198 In the colitis model, a difference in disease severity using MyD88-/- 
Tregs compared to WT Tregs was not observed until 9 weeks post-transplant 
into RAG1-/- mice.220 In our aGVHD model, we start seeing severe aGVHD as 
early as 10 days post-HCT. In the immunization model, the authors waited only 
seven days before measuring Tcon proliferation and pro-inflammatory cytokine 
production.180 We cannot eliminate the possibility based off our data that, in a 
slower disease progression setting, MyD88-/- Tregs do indeed develop a 
suppressive defect. Therefore, the importance of MyD88 signaling in Tregs may 
be highly disease and time dependent. 
 
It has been shown that naïve CD4 T cells require MyD88 signaling through the 
IL-1R in order to overcome Treg-mediated suppression for induction of a Th1 
response.180 While our data suggests that IL-1R signaling in T cells is not 
required for aGVHD induction, left open was the possibility that MyD88 signaling 
in Tcons is required for Treg-mediated suppression in aGVHD. Indeed, when 
transplanting MyD88-/- Tcons with Tregs, we did observe a decrease in aGVHD 
severity and mortality. Interestingly, this phenotype did not depend on MyD88 in 
the Tregs, as transplanting WT or MyD88-/- Tregs with MyD88-/- Tcons showed no 
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difference in aGVHD severity or mortality. We believe that this may be caused by 
loss of signaling through soluble factors, such as IL-6 or TNFα, that act directly or 
indirectly through or on MyD88. Deficiency of IL-1β/MyD88 signaling has already 
been mentioned, but IL-6 has also been implicated in Tcon resistance to Treg-
mediated suppression.221-223 It has been suggested that this is due to blocking of 
Treg-mediated inhibition of IL-2Rα on Tcons.223 We did not check for IL-2Rα 
expression on Tcons during our experiments. Loss of IL-6-producing T cells, but 
not bone marrow cells or non-hematopoietic cells, also prevents aGVHD 
mortality in a murine model, although the mechanism behind this remains 
unexplored.224 Interestingly, similar to our data with MyD88-/- donor T cells, it was 
also found that the absence of IL-6 did not affect the expansion of T cells. As IL-6 
is known to be upregulated by multiple TLR/MyD88 signaling pathways, it is 
possible that reduced IL-6 in MyD88-/- donor T cells could explain our phenotype. 
However, we did not check for IL-6 production in T cells in our models. IL-6 
signaling is known to activate STAT3.225 It is also possible that the absence of 
MyD88 signaling reduces phosphorylated STAT3 levels in the Tcons, which has 
been shown to be important in Tcons for their resistance to Treg suppression.226 
Although STAT3 is not classically thought to be downstream of MyD88, it has 
recently been shown that activation of TLR4 through MyD88, TLR7, or TLR9 
directly leads to phosphorylation of STAT3.211,227,228 Indeed, pSTAT3 Y705 is 
increased significantly in patient CD4 T cells before onset of aGVHD.229 IL-7 and 
IL-15 may also play a role in Tcons-resistance to Tregs during aGVHD.230-232 
Adoptive transfer of T cells into lymphopenic hosts, as would be after irradiation 
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in our aGVHD models, leads to increased availability of IL-7 and IL-15 for the 
transferred T cells. Although a link between IL-7 and MyD88 has yet to be made, 
it has been shown that IL-15 promotes MyD88 expression in T cells.233 How IL-
15 causes MyD88 upregulation and the effect of MyD88 upregulation by IL-15 
has yet to be explored. Tcons could be using these pathways mentioned 
involving MyD88 to redundantly prevent their Treg-mediated suppression, which 
would explain why loss of IL-1R or TLR4 alone was insufficient. 
 
A common convergence of all these pathways is the phosphatidylinositol-3 
kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. This 
pathway helps control many cellular processes, such as proliferation, survival, 
migration, and metabolism.234 It has been suggested that hyper-activation of 
PI3K leads to Tcon resistance to Treg-mediated suppression.235 Indeed, in 
murine models that have genetic deficiencies in proteins that negatively regulate 
PI3K signaling, Tcons are more resistant to Treg-mediated suppression.236,237 
Several cytokine receptors, TNF receptors, TLRs, and T cell costimulatory 
receptors have been shown to activate PI3K signaling.238 While MyD88 has not 
been implicated in all these pathways, we suspect that loss of MyD88 may affect 
enough to prevent hyper-activation of PI3K/ATK/mTOR signaling, thus rendering 
Tcons susceptible to Treg-mediated suppression (Figure 18). Direct targeting of 
mTOR using rapamycin (drug name: Sirolimus) has been extensively studied in 
GVHD and is given to patients routinely as a prophylaxis, with some studies 
suggesting efficacy as a treatment option of aGVHD.239 Recently, in a murine 
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model of aGVHD, direct pan-PI3K inhibition using a small molecule inhibitor 
prevented severe aGVHD development, in part through controlling T cell 
activation.240 However, how pan-PI3K inhibition works on Tcons and Tregs 
specifically was not studied nor the direct mechanism of how pan-PI3K inhibition 
of T cells prevented severe aGVHD development. 
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Figure 18. Proposed mechanism 
Various receptor signaling pathways have been shown to use MyD88 as an 
adaptor protein, including all TLRs except TLR3, the IL-1 superfamily of 
receptors, and recently the IL-15 receptor. We propose a two-pronged approach 
as to how MyD88 Tcons are able to resist Treg-mediated suppression. First, 
signaling through MyD88 activates the PI3K/AKT pathway. Shortly after 
conditioning for transplant, the damage caused by the conditioning leads to 
release of various DAMPs, PAMPs, and alarmins that can activate TLR and IL-
1R superfamily signaling. The loss of lymphocytes after conditioning also causes 
excessive IL-15 to be available. IL-6 is produced and released through IL-1R and 
TLR signaling and can bind to the IL-6R on other Tcons. Both IL-6 signaling and 
MyD88 signaling can activate the PI3K/AKT pathway. Through a yet to be 
defined mechanism, others have proposed that hyper-activation of PI3K/AKT 
signaling promotes resistance of Tcons to suppression by Tregs. Second, we 
show that sST2 production in Tcons is reduced in MyD88-/- Tcons; however, how 
MyD88 regulates sST2 production is still unknown. sST2 released by the Tcon 
can bind free IL-33, preventing IL-33/ST2 signaling on Tregs. IL-33/ST2 signaling 
on Tregs has been shown by numerous groups to promote Treg function. 
Blocking sST2 with a neutralizing antibody has been shown to increase Treg 
frequency and ameliorate experimental aGVHD. We hypothesize that MyD88-/- 
Tcons have less PI3K/AKT activation and secrete less sST2, allowing the Tcons 
to be better repressed by Treg cells. Solid lines: direct effect; Dashed lines: 
indirect effect; dotted lines: proposed effect.  
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4.3 ST2 on T cells 
ST2 on T cells has been found primarily on the Th2 and Treg subsets. ST2 is a 
member of the IL-1R superfamily and signals through MyD88 IL-33/ST2 signaling 
enhances Th2 and Treg activity through increased IL-5 and IL-13 production in 
Th2 cells30,86,111,112 and increased Foxp3 expression in Tregs.65 A soluble form of 
ST2, sST2, sequesters free IL-33 and does not signal. Recently, we have shown 
that T cells, specifically type 1 and type 17 T cells, can produce sST2.75 We and 
others have shown that total ST2-/- T cells ameliorate aGVHD.75,121 We asked 
whether the phenotype of MyD88-/- Tcons in the presence of WT or MyD88-/- 
Tregs observed before would be phenocopied when using ST2-/- Tcons and WT 
or ST2-/- Tregs. Indeed, transplanting ST2-/- Tcons alleviated aGVHD in a similar 
manner regardless of using WT or ST2-/- Tregs, suggesting that ST2/MyD88 
signaling is required for Tcons to overcome Treg-mediated suppression. We did 
notice a small but non-statistically significant difference in aGVHD severity and 
mortality when using ST2-/- Tregs with WT or ST2-/- Tcons compared to using WT 
Tregs with WT or ST2-/- Tcons, suggesting that loss of ST2 on Tregs may impact 
their suppressive capabilities. This would be in line with what has previously 
been shown.65,241 We also show that isolated MyD88-/- CD4 T cells from the 
intestine at day 10 post-HCT express less sST2 and more ST2 compared to 
similarly collected WT CD4 T cells. However, whether MyD88 signaling is directly 
important in sST2 expression by CD4 T cells or whether the decrease in sST2 
expression is due to a decrease in Th1 response is not clear. We hypothesize 
that sST2 produced by Tcons, in a yet-to-be-discovered MyD88-dependent 
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mechanism, is binding to free IL-33, preventing IL-33 binding to ST2 on Tregs. 
This may in part explain the protective phenotype we observed (Figure 18). 
There is evidence that STAT3 and ERK signaling, both of which can be activated 
through MyD88, influence ST2 proximal promoter activity.242 We have not tested 
for STAT3 or ERK activity in our models. As well, the increase in ST2 expression 
may be a compensatory mechanism by the CD4 T cells trying to overcome the 
loss of MyD88. 
 
We and others have attempted to look for ST2 expression via flow cytometry on 
Th1 during aGVHD settings without success. However, recent reports have 
shown that ST2 can indeed be present on Th1 cells. 121,147,243  ST2 signaling on 
Th1 cells helps clear LCMV infection through increased IFN-γ production and is 
dependent on T-bet and STAT4.243 The effect of IL-33 on Th1 differentiation was 
later confirmed using an OVA-immunization murine model as well as human in 
vitro cell cultures.147 The expression of ST2 on the surface only occurred during 
times of inflammation.243 During aGVHD, IL-33 administration during peak 
inflammatory response (days 3-7 post-HCT) enhanced aGVHD severity and 
mortality,121 while IL-33 administration during the peri-transplant period 
ameliorated aGVHD through enhanced ST2+ Treg response.82 This suggests that 
ST2 may be only transiently expressed on Th1 cells, while it is more stably 
expressed on Th2 cells and Tregs. Although an inflammatory response is clearly 
occurring during aGVHD, perhaps this transient expression is the reason that we 
were not able to detect ST2 in our aGVHD model. As we’ve only looked for ST2 
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expression via flow cytometry after day 10 post-HTC and an inflammatory 
response in the host begins as early as day (-)1 pre-transplant after irradiation, it 
is possible that we missed the timepoint in which ST2 is expressed on Th1 cells. 
Further work needs to be done to assess a potential role of ST2/MyD88 signaling 
in promoting a Th1 response early during aGVHD.  
 
A weakness of our mouse model is that the ST2-/- mouse we use has a loss of 
both the membrane and soluble forms of ST2. It is therefore difficult to determine 
whether sST2 production by Tcons or if indeed ST2 is present on Th1 cells and 
loss of ST2 on these cells is more important in the phenotype we observed. 
Development of distinct sST2-/- and membrane ST2-/- mice could really help 
answer these questions. 
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4.4 Therapeutic avenues 
Small molecule inhibitors of MyD88 exist and have been tested in vitro and in 
murine models, with the peptido-mimetic compound ST2825 being the most 
validated.199,244-247 This compound works by preventing MyD88 TIR domain 
homodimerization.199 Treatment of human B cells with ST2825 prevented their 
proliferation when stimulated with CpG in vitro.199 As well, addition of ST2825 to 
astragalus polysaccharide-stimulated RAW 264.7 macrophage cells prevented 
their secretion of proinflammatory cytokines.247 In vivo treatment with this 
inhibitor has been tested in an experimental acute myocardial infarction model,244 
experimental traumatic brain injury model,245 and an experimental seizure 
model;246 however, they have never been tested in an experimental aGVHD 
model nor in a phase 1/2 clinical trial. We used ST2825 in the major mismatch 
model of aGVHD and found no difference in aGVHD severity or mortality. 
However, there could be multiple reasons as to why this experiment did not show 
any differences. First, the length of the treatment period may have been 
insufficient. Beginning earlier or lengthening the treatment period could lead to 
better results. Second, the dosing may not have been correct. We used the 
recommended dose 5 mg/kg twice a day,244 but it may not be a high enough 
dose to see an effect as the pharmacokinetics between naïve and GVHD could 
be quite different (up to 5 times fold difference, i.e. clinical trial on HDAC).248 
Studying the pharmacokinetics and adapting the dose could lead to protection 
against aGVHD.249  
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Undoubtedly, treatment of patients with MyD88 inhibitors could be problematic 
because MyD88 has been shown to be essential for proper myeloid-derived 
suppressor cell (MDSC) protective function during aGVHD.250 MyD88 is also a 
well-known for its role in anti-infection immunity against intracellular 
pathogens.251 Loss of MyD88 signaling post-HCT could greatly increase 
incidences and mortalities due to infection, which can be difficult to treat when 
the immune system is yet to fully recover. We argue that using a ST2 neutralizing 
antibody, as we have previously shown,75 would be better as it would help avoid 
the limitations of using a MyD88 inhibitor. 
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CHAPTER 5: FUTURE DIRECTIONS 
 
Our data suggests that MyD88-/- Tcons are more susceptible to Treg-mediated 
suppression through loss of sST2 production by the donor Tcons. However, the 
exact mechanism for this is still not understood. Our data shows that MyD88-/- 
CD4 T cells isolated from the intestine at day 10 post-HCT express less sST2 
than WT cells collected similarly. The link between MyD88 and sST2 production 
has yet to be elucidated. It’s possible that a transcription factor downstream of 
MyD88 can bind to the promoter region of exon 1B of the ST2 gene, leading to 
expression of sST2. To determine the protein(s) responsible for this link, we 
could start with a thorough search of potential transcription factors that bind to 
the ST2 exon 1B using ENCODE. From this data we would need to find 
transcription factors that are known to be downstream of MyD88 and confirm 
using chromatin immunoprecipitation from CD4 T cells isolated from the intestine 
after aGVHD induction. As well, development of a double knockout of ST2 and 
MyD88 and comparing transcriptome analyses using RNA-seq between the 
double knockout, MyD88-/- T cells, and WT T cells isolated from the intestine 
post-HCT could also help to shed some light on the link between MyD88 and 
sST2 production. 
 
New data has suggested that ST2 is present on Th1 cells transiently during an 
inflammatory response and that ST2 signaling on Th1 cells promotes IFN-γ 
production through a Tbet and STAT4 dependent mechanism.243 Although we 
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have been unable to detect ST2 expression via flow cytometry on Th1 cells 
during aGVHD, this does not mean that ST2 expression did not occur previously 
in these cells. It is possible that we just missed the time point in which ST2 is 
expressed on these cells. To test this we could transplant WT donor BM and T 
cells into lethally irradiated recipients and check in the spleen, MLN, and intestine 
at various early timepoints post-HCT. If we do find expression of ST2 on Th1 
cells, we could perform a flow cytometry analysis, gating first on T-bet+ CD4+ T 
cells, followed by analyzing ST2+ or ST2- cells, and finally look at the IFN-γ 
production from these cells. This would help to show whether ST2+ Th1 cells in 
our aGVHD model express higher IFN-γ, as shown in an LCMV model.243 This 
finding would also help explain in part why loss of MyD88 in the donor Tcons 
ameliorates aGVHD in our mouse models. This also brings up the question as to 
whether ST2+ Th1 cells are resistant to Treg-mediated suppression, as we found 
that ST2-/- Tcons were also susceptible to Treg-mediated suppression. To 
answer this, we could first try to in vitro culture Th1 cells with IL-12 alone or IL-12 
and IL-33, followed by stainings for ST2 and IFN-γ. If we cannot find ST2 
staining, we should at least see increased IFN-γ, as previously suggested.147 
After culturing for 5 days under these conditions, we can remove the media 
containing the cytokines, label these Th1 polarized cells with CFSE, and perform 
a suppressive assay with varying amounts of isolated Tregs. If ST2+ Th1 cells, or 
at least IL-33 responsive Th1 cells, are resistant to Treg-mediated suppression, 
we would expect more dilute CFSE than Th1 cells cultured without IL-33. 
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Although our experiments show that MyD88 is indeed important in Tcons for an 
optimal aGVHD response, the work so far has been confined to murine models. 
Previous work in the lab has shown that blockade of ST2 using a neutralizing 
antibody in a humanized murine model of aGVHD in which the donor T cells 
were of human origin protects against aGVHD, in part through decreased sST2 
production.75 As our work suggests that MyD88 is necessary for optimal sST2 
production by donor T cells during aGVHD, confirming these results in a 
humanized model of aGVHD would be beneficial to help make this work more 
translational. To perform this experiment, we would have to knockdown MyD88 in 
isolated human total T cells and confirm with western blot. After confirming 
sufficient knockdown, we would irradiate NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice, which are deficient for mature lymphocytes and have extremely low NK cell 
activity, and transplant the MyD88 knockdown human T cells and control T cells 
into these mice and record their weight loss and survival.  
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